vignette,question_1,question_2,question_3,question_4,question_5,answer_1,answer_2,answer_3,answer_4,answer_5,marks_1,marks_2,marks_3,marks_4,marks_5,Total_Marks_Achieved
" History of Present Illness
A 58-year-old male presents with a 3-week history of gradually worsening fatigue, weight loss, and fever. Over the past week, he has developed pain and redness in his right hand, which has been intermittently swollen. He denies trauma or any recent infections. He also reports having had bilateral leg pain that worsens with activity but improves with rest. The patient has no history of similar symptoms. He has not been on any new medications, and he denies smoking or alcohol use. His family history is notable for autoimmune diseases, as his father has rheumatoid arthritis. 

  Past Medical History
The patient has a history of hypertension for 10 years, managed with an ACE inhibitor. He has no known history of autoimmune diseases or vasculitis. He underwent a cholecystectomy 5 years ago . 

  Physical Examination
VITALS: BP 135/85 mmHg, pulse 88 bpm, temperature 100.4°F. 
GEN: Ill-appearing, mildly febrile, visibly fatigued. 
CARDIAC: Regular rhythm, no murmurs, Feeble peripheral pulses 
PULM: Clear to auscultation bilaterally. 
ABD: Soft, non-tender, no hepatosplenomegaly. 
MSK: Swelling and erythema of the right hand with tenderness to palpation at the metacarpophalangeal joint. Bilateral calf tenderness with no signs of deep venous thrombosis. 
EXT: No edema, but marked tenderness in the lower extremities. 
SKIN: Petechial rash over the anterior shin. 

  Laboratory Results
WBC: 12 x 103 cells/μL (elevated). Hemoglobin: 11.8 g/dL. ESR: 65 mm/h (elevated). Positive anti-ds DNA antibodies. CRP: 45 mg/L (elevated). Urinalysis: 2+ protein, no blood. Creatinine: 1.2 mg/dL.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Systemic Lupus Erythematosus (SLE)**: The patient's symptoms, such as fatigue, weight loss, fever, joint pain, and skin rash, are consistent with SLE. The presence of anti-dsDNA antibodies, which are specific for SLE, further supports this diagnosis. Additionally, the patient's family history of autoimmune diseases, including rheumatoid arthritis, may also suggest a genetic predisposition to autoimmune disorders.

2. **Rheumatoid Arthritis (RA)**: The patient's symptoms, such as joint pain and swelling, particularly in the hands, are consistent with RA. The presence of elevated ESR and CRP levels also suggests an inflammatory process. However, the presence of anti-dsDNA antibodies and the patient's family history of autoimmune diseases may suggest a more complex autoimmune disorder, such as SLE.

3. **Polyarteritis Nodosa (PAN)**: The patient's symptoms, such as fever, fatigue, and joint pain, are consistent with PAN. The presence of petechial rash and calf tenderness may also suggest vasculitis. However, the patient's laboratory results, including the presence of anti-dsDNA antibodies, may suggest a more complex autoimmune disorder, such as SLE.

It's worth noting that these diagnoses are not mutually exclusive, and the patient may have a combination of these conditions. Further testing and evaluation are needed to confirm the diagnosis.","Here are the findings and risk factors that support each possible diagnosis:

**Systemic Lupus Erythematosus (SLE)**

1. **Anti-dsDNA antibodies**: The presence of anti-dsDNA antibodies is a specific marker for SLE and is found in approximately 70% of patients with SLE.
2. **Positive family history**: The patient's family history of autoimmune diseases, including rheumatoid arthritis, may suggest a genetic predisposition to autoimmune disorders.
3. **Skin rash**: The presence of a petechial rash on the anterior shin is consistent with SLE.
4. **Kidney involvement**: The presence of 2+ proteinuria on urinalysis suggests kidney involvement, which is a common feature of SLE.
5. **Elevated ESR and CRP**: The elevated ESR and CRP levels suggest an inflammatory process, which is consistent with SLE.

**Rheumatoid Arthritis (RA)**

1. **Joint pain and swelling**: The patient's symptoms, such as joint pain and swelling, particularly in the hands, are consistent with RA.
2. **Elevated ESR and CRP**: The elevated ESR and CRP levels suggest an inflammatory process, which is consistent with RA.
3. **Positive family history**: The patient's family history of autoimmune diseases, including rheumatoid arthritis, may suggest a genetic predisposition to autoimmune disorders.
4. **Swollen and erythematous hand**: The presence of a swollen and erythematous hand is consistent with RA.

**Polyarteritis Nodosa (PAN)**

1. **Petechial rash**: The presence of a petechial rash on the anterior shin is consistent with PAN.
2. **Calf tenderness**: The presence of calf tenderness may suggest vasculitis, which is a common feature of PAN.
3. **Elevated ESR and CRP**: The elevated ESR and CRP levels suggest an inflammatory process, which is consistent with PAN.
4. **Kidney involvement**: The presence of 2+ proteinuria on urinalysis suggests kidney involvement, which is a common feature of PAN.

However, the presence of anti-dsDNA antibodies and the patient's family history of autoimmune diseases may suggest a more complex autoimmune disorder, such as SLE, rather than PAN.","Here are the findings that oppose each possible diagnosis:

**Systemic Lupus Erythematosus (SLE)**

1. **Lack of mucocutaneous involvement**: SLE often presents with mucocutaneous involvement, such as oral ulcers, skin lesions, or alopecia. The patient's lack of these symptoms makes SLE less likely.
2. **No neurological symptoms**: SLE can present with neurological symptoms, such as seizures, psychosis, or neuropathy. The patient's lack of these symptoms makes SLE less likely.
3. **Normal complement levels**: SLE is often associated with low complement levels, particularly C3 and C4. The patient's complement levels were not mentioned, but if they were normal, it would make SLE less likely.
4. **No specific SLE-related antibodies**: While anti-dsDNA antibodies are specific for SLE, other antibodies such as anti-Sm, anti-RNP, and anti-SSA/Ro are also commonly found in SLE patients. The patient's lack of these antibodies makes SLE less likely.

**Rheumatoid Arthritis (RA)**

1. **Lack of symmetric joint involvement**: RA typically presents with symmetric joint involvement, particularly in the hands and feet. The patient's unilateral joint involvement makes RA less likely.
2. **No morning stiffness**: RA patients often experience morning stiffness that lasts for hours. The patient's lack of morning stiffness makes RA less likely.
3. **No rheumatoid factor**: Rheumatoid factor is a common antibody found in RA patients. The patient's lack of rheumatoid factor makes RA less likely.
4. **No radiographic evidence of joint damage**: RA patients often have radiographic evidence of joint damage, such as erosions or joint space narrowing. The patient's lack of radiographic evidence makes RA less likely.

**Polyarteritis Nodosa (PAN)**

1. **Lack of systemic symptoms**: PAN often presents with systemic symptoms, such as fever, weight loss, and fatigue. The patient's lack of these symptoms makes PAN less likely.
2. **No renal involvement**: PAN often involves the kidneys, leading to renal failure or hypertension. The patient's lack of renal involvement makes PAN less likely.
3. **No gastrointestinal symptoms**: PAN often involves the gastrointestinal tract, leading to symptoms such as abdominal pain, diarrhea, or weight loss. The patient's lack of gastrointestinal symptoms makes PAN less likely.
4. **No specific PAN-related antibodies**: PAN is often associated with specific antibodies, such as anti-neutrophil cytoplasmic antibodies (ANCA). The patient's lack of these antibodies makes PAN less likely.

These findings do not rule out each diagnosis entirely, but they do suggest that each diagnosis is less likely than the others. Further testing and evaluation are needed to confirm the diagnosis.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Systemic Lupus Erythematosus (SLE)**

The patient's symptoms, such as fatigue, weight loss, fever, joint pain, and skin rash, are consistent with SLE. The presence of anti-dsDNA antibodies, which are specific for SLE, further supports this diagnosis. Additionally, the patient's family history of autoimmune diseases, including rheumatoid arthritis, may suggest a genetic predisposition to autoimmune disorders.

While the patient's lack of mucocutaneous involvement and normal complement levels make SLE less likely, the presence of anti-dsDNA antibodies and the patient's overall clinical picture make SLE the most likely diagnosis.

**Supporting evidence:**

* Anti-dsDNA antibodies
* Positive family history of autoimmune diseases
* Skin rash
* Kidney involvement (2+ proteinuria)
* Elevated ESR and CRP

**Opposing evidence:**

* Lack of mucocutaneous involvement
* Normal complement levels (not mentioned, but would be expected to be low in SLE)

**Differential diagnosis:**

* Rheumatoid Arthritis (RA): While the patient's joint pain and swelling are consistent with RA, the presence of anti-dsDNA antibodies and the patient's overall clinical picture make SLE more likely.
* Polyarteritis Nodosa (PAN): While the patient's petechial rash and calf tenderness are consistent with PAN, the presence of anti-dsDNA antibodies and the patient's overall clinical picture make SLE more likely.

**Treatment:**

* Corticosteroids (e.g., prednisone) to reduce inflammation and suppress the immune system
* Immunosuppressive medications (e.g., hydroxychloroquine, azathioprine) to reduce the risk of flare-ups and prevent organ damage
* Antimalarial medications (e.g., hydroxychloroquine) to reduce inflammation and prevent organ damage
* Regular monitoring of kidney function, blood counts, and liver function to adjust treatment as needed.

Note: This is a hypothetical diagnosis and treatment plan, and actual treatment should be determined by a qualified healthcare professional.","Based on the final diagnosis of Systemic Lupus Erythematosus (SLE), the following additional steps should be taken:

**Initial Steps:**

1. **Confirm the diagnosis**: Repeat the anti-dsDNA antibody test to confirm the presence of these antibodies.
2. **Complete the physical examination**: Perform a thorough physical examination to assess the patient's overall health and identify any other potential symptoms or signs of SLE.
3. **Order additional laboratory tests**: Order the following laboratory tests to assess the patient's kidney function, blood counts, and liver function:
	* Complete Blood Count (CBC)
	* Blood Urea Nitrogen (BUN)
	* Creatinine
	* Liver Function Tests (LFTs)
	* Complement levels (C3 and C4)
4. **Order imaging studies**: Order imaging studies to assess the patient's kidney function and identify any potential kidney damage:
	* Ultrasound of the kidneys
	* Computed Tomography (CT) scan of the kidneys

**Ongoing Management:**

1. **Monitor kidney function**: Regularly monitor the patient's kidney function, including BUN, creatinine, and urine protein levels.
2. **Monitor blood counts**: Regularly monitor the patient's blood counts, including white blood cell count, red blood cell count, and platelet count.
3. **Monitor liver function**: Regularly monitor the patient's liver function, including LFTs.
4. **Monitor for SLE flares**: Regularly monitor the patient for signs of SLE flares, including fever, fatigue, joint pain, and skin rash.
5. **Adjust treatment as needed**: Adjust the patient's treatment plan as needed to manage SLE symptoms and prevent organ damage.

**Long-term Management:**

1. **Regular follow-up appointments**: Schedule regular follow-up appointments with the patient to monitor their condition and adjust treatment as needed.
2. **Lifestyle modifications**: Encourage the patient to make lifestyle modifications, such as:
	* Regular exercise
	* Healthy diet
	* Stress management
	* Avoiding smoking and excessive sun exposure
3. **Medication adherence**: Encourage the patient to adhere to their medication regimen and attend follow-up appointments as scheduled.
4. **Family planning**: Discuss family planning options with the patient, including the risks of SLE transmission to offspring.

**Referral to a Specialist:**

1. **Rheumatologist**: Refer the patient to a rheumatologist for ongoing management and treatment of SLE.
2. **Nephrologist**: Refer the patient to a nephrologist for ongoing management and treatment of kidney disease.
3. **Dermatologist**: Refer the patient to a dermatologist for ongoing management and treatment of skin symptoms.

Note: This is a hypothetical treatment plan, and actual treatment should be determined by a qualified healthcare professional.","{""Score"":3,""Rationale"":""The answer lists Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Polyarteritis Nodosa (a type of vasculitis), all of which match the high‑scoring rubric items, earning full points.""}","{
  ""Score"": 6,
  ""Rationale"": ""Student correctly identified SLE (anti-dsDNA, rash, proteinuria, inflammatory markers), RA (hand swelling, inflammatory markers, family history) and vasculitis (petechial rash, proteinuria, inflammatory markers) as in the high‑scoring example. No mention of peripheral vascular disease, but all three required concepts were present, earning full marks.""
}","{""Score"":2,""Rationale"":""The answer only matches the rubric for Rheumatoid Arthritis by noting absence of morning stiffness, which aligns with the rubric's required concept. No other diagnosis includes the specific rubric-listed features (e.g., renal involvement, butterfly rash, vessel involvement, palpable pulses), so no additional points are awarded.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Systemic Lupus Erythematosus (SLE) and lists supporting findings (fever, weight loss, elevated ESR/CRP, rash, proteinuria) that match the high‑scoring example, thus earning full credit.""}","{""Score"":2,""Rationale"":""The answer includes referral to a rheumatologist, matching one rubric item (2 points). It does not mention performing a kidney biopsy or starting hydroxychloroquine, so those items receive no points.""}",15.0
"History of Present Illness 
A 58-year-old male presents with a 6-month history of progressive fatigue, weight loss, and peripheral edema. He also reports shortness of breath on exertion and difficulty swallowing solid foods for the past 2 months. His urine has become frothy, and he has noticed some tingling sensations in his hands. He denies chest pain, fever, or night sweats. There is no history of hypertension, diabetes, or known heart disease. 
Past Medical History 
The patient has a 10-year history of rheumatoid arthritis, well-controlled with methotrexate. He denies smoking or alcohol use. Family history is negative for any genetic disorders. 
Physical Examination 
VITALS: BP 110/70 mmHg, pulse 90/min, temperature 98.4°F. 
GEN: Thin, pale, fatigued. 
CARDIAC: No murmurs, but there is a slight periorbital edema. 
PULM: Clear to auscultation bilaterally. 
ABD: Mild hepatomegaly (2 cm below the costal margin), no tenderness. 
EXT: Bilateral pedal edema, no erythema or ulcers. 
NEURO: Decreased sensation to light touch in both feet, absent ankle reflexes. 

Laboratory Results
Urinalysis shows 2+ proteinuria, and serum creatinine is 1.5 mg/dL. The BNP is elevated at 550 pg/mL. Serum free light chains are elevated, and a biopsy of abdominal fat reveals amyloid deposits. Echocardiogram shows concentric left ventricular hypertrophy with normal systolic function. Hemoglobin levels within normal range.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Amyloidosis**: The presence of amyloid deposits in the abdominal fat biopsy is a strong indicator of amyloidosis. The patient's symptoms, such as progressive fatigue, weight loss, peripheral edema, and shortness of breath, are also consistent with this diagnosis. Amyloidosis can cause renal failure, heart failure, and neuropathy, which are all evident in this patient.

2. **Rheumatoid Arthritis-associated Amyloidosis**: Given the patient's 10-year history of well-controlled rheumatoid arthritis, it is possible that he has developed amyloidosis as a complication of his chronic inflammatory disease. This type of amyloidosis is known as AA amyloidosis, which is associated with chronic infections or inflammatory diseases.

3. **Light Chain Amyloidosis (AL Amyloidosis)**: The elevated serum free light chains and the presence of amyloid deposits in the abdominal fat biopsy suggest that the patient may have light chain amyloidosis. This type of amyloidosis is associated with plasma cell dyscrasias, such as multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS). The patient's symptoms, such as fatigue, weight loss, and peripheral edema, are consistent with this diagnosis.

These three diagnoses are not mutually exclusive, and it is possible that the patient has a combination of these conditions. Further testing, such as a bone marrow biopsy and serum protein electrophoresis, would be necessary to confirm the diagnosis.","Here are the findings and risk factors that support each possible diagnosis:

**Amyloidosis**

* **Findings:**
 + Presence of amyloid deposits in the abdominal fat biopsy
 + Elevated serum free light chains
 + Proteinuria (2+ proteinuria in urinalysis)
 + Elevated serum creatinine (1.5 mg/dL)
 + Concentric left ventricular hypertrophy with normal systolic function on echocardiogram
* **Risk factors:**
 + Age (58 years)
 + Presence of chronic inflammatory disease (rheumatoid arthritis)
 + No history of hypertension or diabetes, which are common causes of kidney disease

**Rheumatoid Arthritis-associated Amyloidosis (AA Amyloidosis)**

* **Findings:**
 + 10-year history of well-controlled rheumatoid arthritis
 + Elevated serum free light chains
 + Presence of amyloid deposits in the abdominal fat biopsy
 + Proteinuria (2+ proteinuria in urinalysis)
 + Elevated serum creatinine (1.5 mg/dL)
* **Risk factors:**
 + Chronic inflammatory disease (rheumatoid arthritis)
 + Presence of amyloid deposits in the abdominal fat biopsy
 + Elevated serum free light chains, which are associated with chronic inflammation
 + No history of hypertension or diabetes, which are common causes of kidney disease

**Light Chain Amyloidosis (AL Amyloidosis)**

* **Findings:**
 + Elevated serum free light chains
 + Presence of amyloid deposits in the abdominal fat biopsy
 + Proteinuria (2+ proteinuria in urinalysis)
 + Elevated serum creatinine (1.5 mg/dL)
 + Concentric left ventricular hypertrophy with normal systolic function on echocardiogram
* **Risk factors:**
 + Age (58 years)
 + Presence of monoclonal gammopathy (elevated serum free light chains)
 + No history of hypertension or diabetes, which are common causes of kidney disease
 + Family history of plasma cell dyscrasias (not mentioned, but a potential risk factor)

These findings and risk factors support each possible diagnosis, but further testing, such as a bone marrow biopsy and serum protein electrophoresis, would be necessary to confirm the diagnosis.","Here are the findings that oppose each possible diagnosis:

**Amyloidosis**

* **Findings opposing this hypothesis:**
 + **Normal serum free light chains**: Amyloidosis can be associated with elevated serum free light chains, but normal levels would make this diagnosis less likely.
 + **No monoclonal gammopathy**: Amyloidosis is often associated with monoclonal gammopathy, such as multiple myeloma or MGUS. The absence of monoclonal gammopathy would make this diagnosis less likely.
 + **No family history of amyloidosis**: Amyloidosis can have a familial component, and the absence of a family history would make this diagnosis less likely.
* **Findings that were expected but not present:**
 + **More pronounced cardiac involvement**: Amyloidosis can cause significant cardiac involvement, including restrictive cardiomyopathy and heart failure. The patient's echocardiogram showed only concentric left ventricular hypertrophy with normal systolic function, which is less severe than expected.

**Rheumatoid Arthritis-associated Amyloidosis (AA Amyloidosis)**

* **Findings opposing this hypothesis:**
 + **Elevated serum free light chains**: AA amyloidosis is typically associated with normal serum free light chains, whereas the patient's elevated levels suggest AL amyloidosis.
 + **No monoclonal gammopathy**: AA amyloidosis is often associated with chronic inflammatory diseases, such as rheumatoid arthritis, but the patient's elevated serum free light chains suggest AL amyloidosis.
* **Findings that were expected but not present:**
 + **More pronounced renal involvement**: AA amyloidosis can cause significant renal involvement, including nephrotic syndrome and renal failure. The patient's urinalysis showed only proteinuria, which is less severe than expected.

**Light Chain Amyloidosis (AL Amyloidosis)**

* **Findings opposing this hypothesis:**
 + **No monoclonal gammopathy**: AL amyloidosis is typically associated with monoclonal gammopathy, such as multiple myeloma or MGUS. The absence of monoclonal gammopathy would make this diagnosis less likely.
 + **Normal serum free light chains**: AL amyloidosis is often associated with elevated serum free light chains, but normal levels would make this diagnosis less likely.
* **Findings that were expected but not present:**
 + **More pronounced bone marrow involvement**: AL amyloidosis can cause significant bone marrow involvement, including plasmacytosis and bone marrow failure. The patient's bone marrow biopsy was not mentioned, but the absence of bone marrow involvement would make this diagnosis less likely.

These findings oppose each possible diagnosis, but further testing, such as a bone marrow biopsy and serum protein electrophoresis, would be necessary to confirm the diagnosis.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Light Chain Amyloidosis (AL Amyloidosis)**

The patient's elevated serum free light chains, presence of amyloid deposits in the abdominal fat biopsy, proteinuria, and elevated serum creatinine are consistent with AL amyloidosis. The patient's age, absence of hypertension or diabetes, and no history of heart disease also support this diagnosis. While the patient's rheumatoid arthritis could potentially contribute to AA amyloidosis, the elevated serum free light chains and absence of monoclonal gammopathy in AA amyloidosis make AL amyloidosis a more likely diagnosis.

**Supporting evidence:**

* Elevated serum free light chains
* Presence of amyloid deposits in the abdominal fat biopsy
* Proteinuria (2+ proteinuria in urinalysis)
* Elevated serum creatinine (1.5 mg/dL)
* Concentric left ventricular hypertrophy with normal systolic function on echocardiogram

**Opposing evidence:**

* Normal serum free light chains in AA amyloidosis
* No monoclonal gammopathy in AA amyloidosis
* No family history of amyloidosis

**Additional testing:**

* Bone marrow biopsy to confirm the presence of monoclonal gammopathy
* Serum protein electrophoresis to confirm the presence of monoclonal protein
* Immunofixation electrophoresis to confirm the type of monoclonal protein

**Treatment:**

* Chemotherapy to reduce the production of monoclonal protein
* Supportive care to manage symptoms and prevent complications
* Regular monitoring of kidney function and cardiac status

**Prognosis:**

* AL amyloidosis has a variable prognosis, depending on the extent of organ involvement and the effectiveness of treatment.
* Patients with AL amyloidosis often require long-term treatment and close monitoring to manage symptoms and prevent complications.","Based on the final diagnosis of Light Chain Amyloidosis (AL Amyloidosis), the following additional steps should be taken:

**Immediate Steps:**

1. **Bone Marrow Biopsy:** Schedule a bone marrow biopsy to confirm the presence of monoclonal gammopathy and to determine the type of plasma cell dyscrasia.
2. **Serum Protein Electrophoresis (SPEP):** Perform SPEP to confirm the presence of monoclonal protein and to determine its type.
3. **Immunofixation Electrophoresis (IFE):** Perform IFE to confirm the type of monoclonal protein and to determine its molecular characteristics.
4. **Kidney Function Monitoring:** Regularly monitor the patient's kidney function, including serum creatinine and urine protein levels, to assess the extent of renal involvement.
5. **Cardiac Function Monitoring:** Regularly monitor the patient's cardiac function, including echocardiogram and cardiac biomarkers, to assess the extent of cardiac involvement.

**Short-Term Steps:**

1. **Chemotherapy:** Consider initiating chemotherapy to reduce the production of monoclonal protein and to slow disease progression.
2. **Supportive Care:** Provide supportive care, including pain management, to manage symptoms and prevent complications.
3. **Nutritional Support:** Provide nutritional support to ensure adequate caloric intake and to prevent malnutrition.
4. **Infection Prevention:** Implement measures to prevent infections, including vaccination and antimicrobial prophylaxis.

**Long-Term Steps:**

1. **Regular Follow-Up:** Schedule regular follow-up appointments to monitor disease progression and to adjust treatment as needed.
2. **Disease Monitoring:** Regularly monitor the patient's disease status, including serum protein levels, kidney function, and cardiac function.
3. **Treatment Adjustment:** Adjust treatment as needed to optimize disease control and to prevent complications.
4. **Patient Education:** Educate the patient and their family about the disease, its management, and its prognosis.

**Research and Clinical Trials:**

1. **Clinical Trials:** Consider enrolling the patient in clinical trials to evaluate new treatments and to improve disease outcomes.
2. **Research Studies:** Participate in research studies to better understand the disease and to develop new treatments.

**Multidisciplinary Care:**

1. **Multidisciplinary Team:** Assemble a multidisciplinary team, including hematologists, nephrologists, cardiologists, and other specialists, to provide comprehensive care.
2. **Collaborative Care:** Foster collaborative care among team members to ensure optimal disease management and to prevent complications.","{""Score"":1,""Rationale"":""The answer includes Amyloidosis, which matches an item in the rubric (1 mark). It does not include Congestive Cardiac Failure, Chronic Kidney Disease, or Multiple Myeloma, so no additional points are awarded.""}","{
  ""Score"": 2,
  ""Rationale"": ""The answer includes details for Amyloidosis, which matches one of the four concepts in the rubric (2 points). It does not address Congestive Cardiac Failure, Chronic Kidney Disease, or Multiple Myeloma, so no points are awarded for those.""
}","{""Score"":0,""Rationale"":""The response does not include any of the required concepts from the high‑scoring example (no opposing findings for amyloidosis, discussion of congestive cardiac failure, CKD, or amyloid deposition on biopsy with multiple myeloma). It provides unrelated opposing findings, so no points are awarded.""}","{""Score"":2,""Rationale"":""The answer correctly identifies amyloidosis (specifically AL amyloidosis) and cites biopsy‑confirmed amyloid deposits and proteinuria, matching the key concepts in the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes Bone Marrow Biopsy, which matches one of the three required items in the rubric. It does not mention Cardiac MRI or Renal biopsy, so only 2 of the 6 possible points are earned.""}",7.0
"History of Present Illness
A 59-year-old male presents with swelling and pain in his right leg that started 3 days ago. He was discharged from the hospital 2 weeks ago after undergoing knee replacement surgery, during which he received prophylactic low molecular weight heparin. He reports intermittent fever and recent episodes of palpitations. He denies chest pain, shortness of breath, or prior deep vein thrombosis (DVT). 

  Past Medical History
He has a history of osteoarthritis requiring knee replacement. He has hypertension, controlled with amlodipine, and a history of dyslipidemia. He has no history of malignancy or clotting disorders. 

  Physical Examination
VITALS: BP 125/80 mmHg, pulse 102/min, temperature 99.6°F. 
GEN: Appears mildly uncomfortable. 
CARDIAC: Regular rhythm, no murmurs or gallops. 
PULM: Clear to auscultation bilaterally. 
ABD: Soft, non-tender. 
EXT: Right leg swollen with mild erythema and tenderness along the femoral vein. Homans' sign is positive. No ulcers or skin changes. 
SKIN: Petechiae on both forearms. 

  Laboratory Results
Platelet count has decreased to 58 x 10³/μL from 210 x 10³/μL 10 days ago. D-dimer is elevated at 5.2 μg/mL. The Heparin-PF4 antibody test is positive. Ultrasound reveals a thrombus in the right femoral vein.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's history and laboratory results, here are three possible diagnoses:

1. **Heparin-Induced Thrombocytopenia (HIT)**: This is a serious complication of heparin therapy, characterized by a decrease in platelet count and the formation of antibodies against the heparin-PF4 complex. The patient's history of recent heparin use, positive heparin-PF4 antibody test, and decreased platelet count are consistent with HIT.

2. **Deep Vein Thrombosis (DVT)**: The patient's symptoms of swelling, pain, and erythema in the right leg, along with the ultrasound findings of a thrombus in the right femoral vein, are consistent with DVT.

3. **Heparin-Induced Thrombosis and Thrombocytopenia (HITT)**: This is a rare but serious condition that occurs when a patient develops both HIT and a new thrombosis, often in a different location from the original site of heparin use. The patient's history of recent heparin use, positive heparin-PF4 antibody test, decreased platelet count, and new thrombosis in the right femoral vein are consistent with HITT.

It's worth noting that the patient's symptoms of palpitations and petechiae on the forearms may also be related to HIT, as these can be manifestations of the condition.","Here are the findings and risk factors that support each possible diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

1. **Recent heparin use**: The patient was discharged from the hospital 2 weeks ago after undergoing knee replacement surgery, during which he received prophylactic low molecular weight heparin.
2. **Decreased platelet count**: The patient's platelet count has decreased to 58 x 10³/μL from 210 x 10³/μL 10 days ago.
3. **Positive heparin-PF4 antibody test**: The heparin-PF4 antibody test is a specific test for HIT, and a positive result indicates the presence of antibodies against the heparin-PF4 complex.
4. **New thrombosis**: The patient has developed a new thrombosis in the right femoral vein, which is a common complication of HIT.
5. **Petechiae on the forearms**: Petechiae are small, pinpoint bleeding spots that can occur in patients with HIT due to platelet dysfunction.

**Deep Vein Thrombosis (DVT)**

1. **Swelling and pain in the right leg**: The patient reports swelling and pain in the right leg, which are common symptoms of DVT.
2. **Erythema and tenderness along the femoral vein**: The patient has erythema and tenderness along the femoral vein, which are signs of inflammation and thrombosis.
3. **Homans' sign is positive**: Homans' sign is a clinical test for DVT, and a positive result indicates the presence of a thrombosis.
4. **Ultrasound findings of a thrombus in the right femoral vein**: The ultrasound findings confirm the presence of a thrombus in the right femoral vein.

**Heparin-Induced Thrombosis and Thrombocytopenia (HITT)**

1. **Recent heparin use**: The patient was discharged from the hospital 2 weeks ago after undergoing knee replacement surgery, during which he received prophylactic low molecular weight heparin.
2. **Decreased platelet count**: The patient's platelet count has decreased to 58 x 10³/μL from 210 x 10³/μL 10 days ago.
3. **Positive heparin-PF4 antibody test**: The heparin-PF4 antibody test is a specific test for HIT, and a positive result indicates the presence of antibodies against the heparin-PF4 complex.
4. **New thrombosis in a different location**: The patient has developed a new thrombosis in the right femoral vein, which is a different location from the original site of heparin use.
5. **Palpitations and petechiae on the forearms**: These symptoms may be related to HIT, as they can be manifestations of the condition.

It's worth noting that the patient's symptoms and laboratory results are most consistent with HIT, as the positive heparin-PF4 antibody test and decreased platelet count are specific findings for this condition.","Here are the findings that oppose each possible diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

1. **No history of previous HIT**: The patient has no history of previous HIT, which is a risk factor for developing HIT.
2. **No other thrombocytopenia risk factors**: The patient has no other risk factors for thrombocytopenia, such as malignancy, autoimmune disorders, or recent use of other medications that can cause thrombocytopenia.
3. **Normal platelet count before heparin use**: The patient's platelet count was normal before heparin use, which is expected in HIT.
4. **No thrombosis in a different location**: The patient's new thrombosis is in the same location as the original site of heparin use, which is not typical of HITT.
5. **No other symptoms of HIT**: The patient does not have other symptoms of HIT, such as fever, chills, or rash.

**Deep Vein Thrombosis (DVT)**

1. **No risk factors for DVT**: The patient has no risk factors for DVT, such as recent surgery, immobility, or malignancy.
2. **No other symptoms of DVT**: The patient does not have other symptoms of DVT, such as swelling, pain, or redness in the affected limb.
3. **Normal platelet count**: The patient's platelet count is decreased, which is not typical of DVT.
4. **No other laboratory findings of DVT**: The patient's laboratory results do not show other findings typical of DVT, such as elevated D-dimer levels or abnormal coagulation studies.
5. **No history of previous DVT**: The patient has no history of previous DVT, which is a risk factor for developing DVT.

**Heparin-Induced Thrombosis and Thrombocytopenia (HITT)**

1. **No other thrombosis risk factors**: The patient has no other risk factors for thrombosis, such as malignancy, autoimmune disorders, or recent use of other medications that can cause thrombosis.
2. **No other symptoms of HITT**: The patient does not have other symptoms of HITT, such as fever, chills, or rash.
3. **Normal platelet count before heparin use**: The patient's platelet count was normal before heparin use, which is expected in HITT.
4. **No thrombosis in a different location**: The patient's new thrombosis is in the same location as the original site of heparin use, which is not typical of HITT.
5. **No other laboratory findings of HITT**: The patient's laboratory results do not show other findings typical of HITT, such as elevated D-dimer levels or abnormal coagulation studies.

It's worth noting that the patient's symptoms and laboratory results are most consistent with HIT, as the positive heparin-PF4 antibody test and decreased platelet count are specific findings for this condition.","Based on the patient's history, physical examination, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

The patient's recent use of heparin, positive heparin-PF4 antibody test, decreased platelet count, and new thrombosis in the right femoral vein are all consistent with HIT. The patient's symptoms of palpitations and petechiae on the forearms may also be related to HIT. While the patient's new thrombosis is in the same location as the original site of heparin use, this is not uncommon in HIT, and the patient's overall clinical picture is most consistent with this diagnosis.

**Treatment Plan**

The patient will need to be treated with an alternative anticoagulant, such as argatroban or bivalirudin, to prevent further thrombosis and to manage the existing thrombosis. The patient will also need to be monitored closely for signs of bleeding or thrombosis.

**Discharge Instructions**

The patient will need to be discharged to a rehabilitation facility or home with close monitoring and follow-up. The patient will need to be instructed on the signs and symptoms of HIT and the importance of reporting any new symptoms to their healthcare provider. The patient will also need to be instructed on the proper use of their anticoagulant medication and the importance of adhering to their treatment plan.

**Follow-up**

The patient will need to be followed up closely in the hospital or clinic to monitor their response to treatment and to adjust their treatment plan as needed. The patient will need to have regular platelet counts and coagulation studies to monitor their response to treatment and to detect any signs of bleeding or thrombosis.","Based on the final diagnosis of Heparin-Induced Thrombocytopenia (HIT), the following additional steps should be taken:

**Immediate Steps**

1. **Discontinue heparin**: The patient should be immediately discontinued from heparin therapy to prevent further thrombosis and to manage the existing thrombosis.
2. **Initiate alternative anticoagulant**: The patient should be started on an alternative anticoagulant, such as argatroban or bivalirudin, to prevent further thrombosis and to manage the existing thrombosis.
3. **Monitor platelet count**: The patient's platelet count should be closely monitored to ensure that it is increasing and to detect any signs of bleeding or thrombosis.
4. **Monitor coagulation studies**: The patient's coagulation studies, such as PT and aPTT, should be closely monitored to ensure that they are within normal limits and to detect any signs of bleeding or thrombosis.

**Short-term Steps**

1. **Repeat heparin-PF4 antibody test**: The patient's heparin-PF4 antibody test should be repeated to confirm the diagnosis of HIT and to monitor the patient's response to treatment.
2. **Monitor for signs of bleeding or thrombosis**: The patient should be closely monitored for signs of bleeding or thrombosis, such as petechiae, ecchymoses, or new thrombosis.
3. **Adjust treatment plan as needed**: The patient's treatment plan should be adjusted as needed to ensure that the patient is receiving the most effective and safe treatment for HIT.

**Long-term Steps**

1. **Monitor for long-term complications**: The patient should be monitored for long-term complications of HIT, such as chronic thrombocytopenia or thrombosis.
2. **Consider alternative anticoagulants**: The patient may need to be switched to alternative anticoagulants, such as warfarin or aspirin, to prevent further thrombosis.
3. **Monitor for signs of HIT recurrence**: The patient should be closely monitored for signs of HIT recurrence, such as new thrombosis or thrombocytopenia.

**Patient Education**

1. **Educate the patient on HIT**: The patient should be educated on the diagnosis of HIT, its symptoms, and its treatment.
2. **Educate the patient on anticoagulant therapy**: The patient should be educated on the proper use of anticoagulant therapy, including the importance of adhering to their treatment plan and monitoring for signs of bleeding or thrombosis.
3. **Educate the patient on signs of HIT recurrence**: The patient should be educated on the signs of HIT recurrence, including new thrombosis or thrombocytopenia, and the importance of reporting any new symptoms to their healthcare provider.","{""Score"":2,""Rationale"":""The answer includes Heparin-Induced Thrombocytopenia (HIT) and Deep Vein Thrombosis (DVT), which match two of the three required items. The third item listed (Heparin-Induced Thrombosis and Thrombocytopenia) does not match the required 'Fat embolism', so no point for the third.""}","{""Score"":4,""Rationale"":""The answer includes correct details for Heparin-Induced Thrombocytopenia (HIT) and Deep Vein Thrombosis (DVT), matching two rubric concepts (2 points each). It does not mention Fat Embolism, the third required concept, so no points are awarded for that.""}","{
  ""Score"": 0,
  ""Rationale"": ""The student's answer does not match any of the concepts in the high scoring example. For HIT they list opposing findings, whereas the rubric states there are no opposing findings. They do not address Fat Embolism at all, and their points for DVT do not align with the rubric's reasoning. Therefore no points are awarded.""
}","{""Score"":2,""Rationale"":""The answer correctly identifies Heparin-Induced Thrombocytopenia (HIT) and includes the key concepts from the rubric: recent heparin use, positive Heparin-PF4 antibody test, thrombocytopenia, new thrombosis, and petechiae, matching the high‑scoring example.""}","{""Score"":6,""Rationale"":""The answer includes all three rubric items: discontinuing heparin, initiating an alternative anticoagulant (argatroban), and closely monitoring platelet count. Extra content does not affect the full credit.""}",14.0
"History of Present Illness
A 44-year-old female presents with a 6-month history of unintentional weight gain, especially in her abdomen and face. She notes the appearance of purple striae on her abdomen and has recently developed increased acne and facial hair growth. She reports fatigue, insomnia, and mood swings. Over the last month, she has had progressive weakness in her legs, which is most noticeable when climbing stairs.

Past Medical History
The patient has a history of polycystic ovary syndrome (PCOS), for which she has been treated intermittently with oral contraceptives. She denies any history of diabetes or previous steroid use.

Physical Examination
VITALS: BP 170/110 mmHg, pulse 82/min, temperature 98.5°F.
GEN: Overweight, with moon facies and a central distribution of fat.
CARDIAC: Regular rhythm, no murmurs.
PULM: Clear to auscultation bilaterally.
ABD: Obese with prominent abdominal striae and a rounded abdomen.
EXT: Bilateral proximal muscle weakness, especially in the thighs.
SKIN: Purple striae on the abdomen, mild acne on the back and face.

Laboratory Results
Serum cortisol levels are elevated, with a 24-hour urine cortisol excretion of 500 μg/day (normal: <50 μg/day). ACTH is raised, and MRI of the pituitary gland shows a small adenoma.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Cushing's Syndrome**: This is a condition caused by excess levels of cortisol in the body, which can be due to various reasons such as a pituitary adenoma (as seen in this patient), adrenal gland tumors, or long-term use of corticosteroid medications. The patient's symptoms, such as weight gain, purple striae, acne, and facial hair growth, are consistent with Cushing's syndrome.

2. **Pituitary Adenoma (Cushing's Disease)**: This is a specific type of Cushing's syndrome caused by a pituitary adenoma that secretes excess adrenocorticotropic hormone (ACTH), leading to increased cortisol production. The patient's MRI findings of a small adenoma in the pituitary gland support this diagnosis.

3. **Adrenal Gland Hyperfunction**: Although less likely in this case, adrenal gland hyperfunction could also be a possible diagnosis, where the adrenal glands produce excess cortisol independently of ACTH stimulation. However, the patient's elevated ACTH levels and pituitary adenoma suggest that the primary issue is at the pituitary level.

These diagnoses are not mutually exclusive, and further evaluation and testing may be necessary to confirm the underlying cause of the patient's symptoms.","Here are the findings and risk factors supporting each possible diagnosis:

**Cushing's Syndrome**

* **Findings:**
	+ Elevated serum cortisol levels (500 μg/day)
	+ Elevated 24-hour urine cortisol excretion
	+ Purple striae on the abdomen
	+ Central obesity (moon facies, buffalo hump)
	+ Hirsutism (facial hair growth)
	+ Acne
	+ Hypertension (BP 170/110 mmHg)
* **Risk factors:**
	+ History of polycystic ovary syndrome (PCOS), which may be associated with insulin resistance and increased cortisol production
	+ Family history of Cushing's syndrome or other endocrine disorders
	+ Previous use of corticosteroid medications (although the patient denies this)

**Pituitary Adenoma (Cushing's Disease)**

* **Findings:**
	+ Elevated ACTH levels
	+ MRI findings of a small adenoma in the pituitary gland
	+ Central obesity and other symptoms of Cushing's syndrome
* **Risk factors:**
	+ Family history of pituitary adenomas or other endocrine disorders
	+ Previous head trauma or radiation exposure
	+ Genetic predisposition (e.g., multiple endocrine neoplasia type 1)

**Adrenal Gland Hyperfunction**

* **Findings:**
	+ Elevated serum cortisol levels (although this could be due to ACTH stimulation)
	+ Hypertension (BP 170/110 mmHg)
	+ Central obesity and other symptoms of Cushing's syndrome
* **Risk factors:**
	+ Family history of adrenal gland disorders or other endocrine disorders
	+ Previous use of corticosteroid medications (although the patient denies this)
	+ Genetic predisposition (e.g., congenital adrenal hyperplasia)

It's worth noting that the patient's history of PCOS and the presence of a pituitary adenoma make Cushing's disease a more likely diagnosis. However, further evaluation and testing, such as a high-dose dexamethasone suppression test, may be necessary to confirm the diagnosis.","Here are the findings opposing each possible diagnosis:

**Cushing's Syndrome**

* **Findings opposing this hypothesis:**
	+ **Normal ACTH levels**: Elevated ACTH levels are typically seen in Cushing's disease, which is caused by a pituitary adenoma. Normal ACTH levels would suggest that the primary issue is not at the pituitary level.
	+ **Lack of response to high-dose dexamethasone suppression test**: This test is used to diagnose Cushing's syndrome by suppressing cortisol production with high doses of dexamethasone. Failure to suppress cortisol production would suggest that the primary issue is not Cushing's syndrome.
	+ **No family history of Cushing's syndrome or other endocrine disorders**: A family history of Cushing's syndrome or other endocrine disorders would increase the likelihood of Cushing's syndrome.
* **Findings that were expected but not present:**
	+ **No history of diabetes or glucose intolerance**: Cushing's syndrome is often associated with insulin resistance and glucose intolerance.
	+ **No history of hypertension in family members**: Hypertension is a common feature of Cushing's syndrome, and a family history of hypertension would increase the likelihood of this diagnosis.

**Pituitary Adenoma (Cushing's Disease)**

* **Findings opposing this hypothesis:**
	+ **Normal serum cortisol levels**: Elevated serum cortisol levels are typically seen in Cushing's disease, which is caused by a pituitary adenoma. Normal cortisol levels would suggest that the primary issue is not at the pituitary level.
	+ **No MRI findings of a pituitary adenoma**: The presence of a pituitary adenoma is a hallmark of Cushing's disease. The absence of such findings would suggest that the primary issue is not at the pituitary level.
	+ **No family history of pituitary adenomas or other endocrine disorders**: A family history of pituitary adenomas or other endocrine disorders would increase the likelihood of Cushing's disease.
* **Findings that were expected but not present:**
	+ **No history of head trauma or radiation exposure**: Head trauma or radiation exposure can increase the risk of developing a pituitary adenoma.
	+ **No history of other endocrine disorders**: Cushing's disease is often associated with other endocrine disorders, such as acromegaly or prolactinoma.

**Adrenal Gland Hyperfunction**

* **Findings opposing this hypothesis:**
	+ **Elevated ACTH levels**: Elevated ACTH levels are typically seen in Cushing's disease, which is caused by a pituitary adenoma. Elevated ACTH levels would suggest that the primary issue is not at the adrenal gland level.
	+ **No MRI findings of an adrenal gland tumor**: The presence of an adrenal gland tumor is a hallmark of adrenal gland hyperfunction. The absence of such findings would suggest that the primary issue is not at the adrenal gland level.
	+ **No family history of adrenal gland disorders or other endocrine disorders**: A family history of adrenal gland disorders or other endocrine disorders would increase the likelihood of adrenal gland hyperfunction.
* **Findings that were expected but not present:**
	+ **No history of previous use of corticosteroid medications**: Previous use of corticosteroid medications can increase the risk of developing adrenal gland hyperfunction.
	+ **No history of other endocrine disorders**: Adrenal gland hyperfunction is often associated with other endocrine disorders, such as congenital adrenal hyperplasia.","Based on the patient's symptoms, laboratory results, and the findings supporting and opposing each possible diagnosis, I would make the following final diagnosis:

**Final Diagnosis:** Cushing's Disease

**Reasoning:**

* The patient's symptoms, such as weight gain, purple striae, acne, and facial hair growth, are consistent with Cushing's syndrome.
* The patient's elevated serum cortisol levels and 24-hour urine cortisol excretion are also consistent with Cushing's syndrome.
* The patient's elevated ACTH levels and MRI findings of a small adenoma in the pituitary gland are highly suggestive of Cushing's disease, which is a specific type of Cushing's syndrome caused by a pituitary adenoma.
* The patient's lack of response to high-dose dexamethasone suppression test is not mentioned, but if the patient had been tested, a failure to suppress cortisol production would have further supported the diagnosis of Cushing's disease.
* The patient's family history of PCOS and the presence of a pituitary adenoma make Cushing's disease a more likely diagnosis than adrenal gland hyperfunction.

**Treatment Plan:**

* The patient will undergo surgical resection of the pituitary adenoma to remove the source of excess ACTH production.
* Post-operative management will include monitoring of cortisol levels and ACTH production to ensure that the adenoma has been completely removed.
* The patient may also require replacement therapy with glucocorticoids and mineralocorticoids to replace the deficient hormones produced by the adrenal glands.

**Follow-up:**

* The patient will require regular follow-up appointments to monitor for any signs of recurrence or complications.
* The patient will also require regular monitoring of cortisol levels and ACTH production to ensure that the treatment is effective and to detect any signs of recurrence early.","Based on the final diagnosis of Cushing's disease, the following additional steps should be taken:

**Additional Steps:**

1. **Surgical resection of the pituitary adenoma:**
	* The patient will undergo a transsphenoidal surgery to remove the pituitary adenoma.
	* The surgery will be performed by a neurosurgeon or an endocrine surgeon with expertise in pituitary surgery.
	* The patient will be closely monitored during and after the surgery to ensure that the adenoma is completely removed and that there are no complications.
2. **Post-operative management:**
	* The patient will require close monitoring of cortisol levels and ACTH production to ensure that the adenoma has been completely removed.
	* The patient may require replacement therapy with glucocorticoids and mineralocorticoids to replace the deficient hormones produced by the adrenal glands.
	* The patient will also require regular follow-up appointments to monitor for any signs of recurrence or complications.
3. **Monitoring of cortisol levels and ACTH production:**
	* The patient will require regular monitoring of cortisol levels and ACTH production to ensure that the treatment is effective and to detect any signs of recurrence early.
	* The patient may require regular blood tests to monitor cortisol levels and ACTH production.
4. **Imaging studies:**
	* The patient may require imaging studies, such as MRI or CT scans, to monitor for any signs of recurrence or complications.
5. **Endocrine evaluation:**
	* The patient will require regular endocrine evaluation to monitor for any signs of hypopituitarism or other endocrine disorders.
6. **Lifestyle modifications:**
	* The patient will require lifestyle modifications, such as a healthy diet and regular exercise, to manage the symptoms of Cushing's disease.
7. **Psychological evaluation:**
	* The patient may require psychological evaluation to manage the emotional and psychological effects of Cushing's disease.

**Additional Tests:**

1. **High-dose dexamethasone suppression test:**
	* The patient may require a high-dose dexamethasone suppression test to confirm the diagnosis of Cushing's disease.
2. **24-hour urine free cortisol:**
	* The patient may require a 24-hour urine free cortisol test to monitor cortisol levels and detect any signs of recurrence.
3. **ACTH stimulation test:**
	* The patient may require an ACTH stimulation test to monitor ACTH production and detect any signs of recurrence.

**Additional Medications:**

1. **Glucocorticoids:**
	* The patient may require glucocorticoids to replace the deficient hormones produced by the adrenal glands.
2. **Mineralocorticoids:**
	* The patient may require mineralocorticoids to replace the deficient hormones produced by the adrenal glands.
3. **Anti-hypertensive medications:**
	* The patient may require anti-hypertensive medications to manage hypertension.
4. **Anti-diabetic medications:**
	* The patient may require anti-diabetic medications to manage glucose intolerance.","{""Score"":2,""Rationale"":""The answer includes Cushing's Syndrome and Cushing's Disease (Cushing's Disease), matching two of the three required concepts, but does not include Polycystic Ovary Syndrome (PCOS).""}","{
  ""Score"": 4,
  ""Rationale"": ""The answer includes appropriate findings for Cushing's Disease and Cushing's Syndrome, matching concepts from the rubric, earning 2 points each. However, it does not provide the required PCOS description, so no points are awarded for that category.""
}","{""Score"":0,""Rationale"":""The answer does not provide the opposing findings listed in the rubric for Cushing's Disease, Cushing’s Syndrome/Exogenous Steroids, or PCOS; it addresses different diagnoses and concepts, so no points are awarded.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Cushing's Disease and includes the key features listed in the rubric (weight gain, purple striae, elevated cortisol, pituitary adenoma), matching the high‑scoring example.""}","{""Score"":4,""Rationale"":""Student mentions a high-dose dexamethasone suppression test (matches the dexamethasone test) and references monitoring ACTH production (equivalent to ACTH measurement). No mention of referral to endocrinology, so only two of the three rubric items are present, earning 4 of 6 points.""}",12.0
"History Of Present Illness 
A 76-year-old male presents to his primary care physician with complaints of back and thigh pain lasting for 2 weeks. He reports no pain while sitting or lying down, but walking induces severe pain in his lower back, buttocks, and calves. He also feels fatigued and slightly febrile. A referring cardiologist noted recent test results, since the onset of pain, showing a new anemia and azotemia. Notably, a few days prior to the onset of his symptoms, the patient underwent coronary angioplasty, during which he received heparin for 48 hours.
Past Medical History 
Ischemic heart disease had first been diagnosed ten years earlier, at which time a coronary artery bypass procedure was done. 
Physical Examination 
VITALS: 99.6° F.; pulse was 94/min and regular; BP was 110/88 mmHg. 
GEN: Well appearing 
CARDS: There is a grade III/VI apical systolic murmur. 
PULM: Lungs are clear to auscultation bilaterally, no wheezing, or consolidations noted. 
ABD: Soft, non-tender to palpation 
MSK: He does not have tenderness of his spine or pelvis. Spinal mobility is normal, as is the mobility of his hips. Standing is painless; however, pain is experienced in his low back, buttocks and calves within a minute of feeble running in place. The pain disappears shortly after exercise is discontinued. 
EXT: Peripheral pulses were symmetrically reduced, but palpable. The neurological examination was normal. 
SKIN: Patient has a purple, red, lacy rash over his low back and buttocks. 
Laboratory 
WBC of 11.5 x 103 cells /μL; differential of 64% segs, 20% lymphocytes, 3% monocytes, 12% eosinophils and 1% basophil. The hematocrit was 28% and the platelet count was 315 x 103 /μL. The erythrocyte sedimentation rate was 99 mm/h. Urinalysis was normal except for 2+ proteinuria. Serum creatinine was 4.0 mg/dL; sodium was 145 mEq/L; potassium 4.0 mEq/L; chloride 105 mEq/L. SGOT was 27 U/L; GGT was 90 U/L; alkaline phosphatase was 153 U/L.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Thrombotic Thrombocytopenic Purpura (TTP)**: The patient's recent coronary angioplasty, new anemia, azotemia, and thrombocytopenia (low platelet count) could be indicative of TTP. The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks also supports this diagnosis.

2. **Heparin-Induced Thrombocytopenia (HIT)**: The patient received heparin for 48 hours during coronary angioplasty, and now has a low platelet count. HIT is a known complication of heparin therapy, and the patient's symptoms, including the rash, could be indicative of this condition.

3. **Cholesterol Embolism Syndrome (CES)**: The patient's recent coronary angioplasty, new anemia, azotemia, and thrombocytopenia could also be indicative of CES. The presence of a purple, red, lacy rash on the patient's low back and buttocks, as well as the patient's symptoms of back and thigh pain, could be indicative of cholesterol emboli in the lower extremities.

These diagnoses are not mutually exclusive, and further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms.","Here are the findings and risk factors that support each possible diagnosis:

**Thrombotic Thrombocytopenic Purpura (TTP)**

* **Recent coronary angioplasty**: TTP can be triggered by certain medical procedures, including cardiac catheterization and angioplasty.
* **New anemia and azotemia**: TTP is characterized by microangiopathic hemolytic anemia, which can cause anemia and azotemia.
* **Thrombocytopenia (low platelet count)**: TTP is characterized by thrombocytopenia, which can be severe.
* **Purpura**: The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks is a classic finding in TTP.
* **Elevated erythrocyte sedimentation rate (ESR)**: TTP can cause inflammation, which can lead to an elevated ESR.
* **Recent use of heparin**: Heparin can trigger TTP in some patients.

**Heparin-Induced Thrombocytopenia (HIT)**

* **Recent use of heparin**: HIT is a known complication of heparin therapy, and the patient received heparin for 48 hours during coronary angioplasty.
* **Thrombocytopenia (low platelet count)**: HIT is characterized by thrombocytopenia, which can be severe.
* **New anemia and azotemia**: HIT can cause microangiopathic hemolytic anemia, which can lead to anemia and azotemia.
* **Purpura**: The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks is a classic finding in HIT.
* **Elevated ESR**: HIT can cause inflammation, which can lead to an elevated ESR.

**Cholesterol Embolism Syndrome (CES)**

* **Recent coronary angioplasty**: CES can be triggered by certain medical procedures, including cardiac catheterization and angioplasty.
* **New anemia and azotemia**: CES can cause microangiopathic hemolytic anemia, which can lead to anemia and azotemia.
* **Thrombocytopenia (low platelet count)**: CES can cause thrombocytopenia, which can be severe.
* **Purpura**: The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks is a classic finding in CES.
* **Elevated ESR**: CES can cause inflammation, which can lead to an elevated ESR.
* **Reduced peripheral pulses**: CES can cause emboli in the lower extremities, which can lead to reduced peripheral pulses.
* **Proteinuria**: CES can cause renal damage, which can lead to proteinuria.

These findings and risk factors support the hypothesis that the patient's symptoms are due to one of these three possible diagnoses. Further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms.","Here are the findings that oppose each possible diagnosis, or findings that were expected but not present:

**Thrombotic Thrombocytopenic Purpura (TTP)**

* **Lack of neurological symptoms**: TTP often presents with neurological symptoms such as headache, confusion, and seizures. The patient's neurological examination was normal.
* **Normal renal function**: TTP can cause renal failure, but the patient's serum creatinine was only 4.0 mg/dL, which is not significantly elevated.
* **No schistocytes on peripheral smear**: TTP is characterized by the presence of schistocytes (fragmented red blood cells) on the peripheral smear. The patient's laboratory results do not mention the presence of schistocytes.
* **No fever**: TTP often presents with fever, but the patient's temperature was only slightly elevated (99.6°F).

**Heparin-Induced Thrombocytopenia (HIT)**

* **Lack of thrombosis**: HIT is characterized by the formation of antibodies that activate platelets, leading to thrombosis. The patient's laboratory results do not mention the presence of thrombosis.
* **Normal coagulation studies**: HIT is characterized by abnormal coagulation studies, including prolonged activated partial thromboplastin time (aPTT) and thrombin time (TT). The patient's laboratory results do not mention abnormal coagulation studies.
* **No history of previous HIT**: HIT is more likely to occur in patients who have had previous exposure to heparin. The patient's medical history does not mention previous HIT.
* **No other signs of HIT**: HIT is characterized by a range of symptoms, including skin lesions, renal failure, and respiratory distress. The patient's symptoms do not match this profile.

**Cholesterol Embolism Syndrome (CES)**

* **Lack of cholesterol crystals on urinalysis**: CES is characterized by the presence of cholesterol crystals in the urine. The patient's urinalysis was normal.
* **No history of atherosclerotic disease**: CES is more likely to occur in patients with a history of atherosclerotic disease. The patient's medical history does not mention atherosclerotic disease.
* **Normal lipid profile**: CES is more likely to occur in patients with a high lipid profile. The patient's lipid profile is not mentioned in the laboratory results.
* **No other signs of CES**: CES is characterized by a range of symptoms, including renal failure, hypertension, and neurological symptoms. The patient's symptoms do not match this profile.

These findings oppose each possible diagnosis, or findings that were expected but not present. Further testing and evaluation would be necessary to determine the underlying cause of the patient's symptoms.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Heparin-Induced Thrombocytopenia (HIT)**

The patient's recent use of heparin during coronary angioplasty, new anemia, azotemia, and thrombocytopenia (low platelet count) are all consistent with HIT. The presence of a purple, red, lacy rash (purpura) on the patient's low back and buttocks is also a classic finding in HIT. While the patient's symptoms do not match the typical profile of HIT, the presence of these findings and the patient's recent exposure to heparin make HIT the most likely diagnosis.

**Supporting evidence:**

* Recent use of heparin during coronary angioplasty
* New anemia and azotemia
* Thrombocytopenia (low platelet count)
* Purpura
* Elevated erythrocyte sedimentation rate (ESR)

**Opposing evidence:**

* Lack of thrombosis
* Normal coagulation studies
* No history of previous HIT
* No other signs of HIT

**Differential diagnosis:**

* Thrombotic Thrombocytopenic Purpura (TTP)
* Cholesterol Embolism Syndrome (CES)

**Treatment:**

* Discontinue heparin and any other anticoagulant medications
* Administer platelet transfusions as needed
* Consider alternative anticoagulant medications, such as argatroban or bivalirudin
* Monitor the patient's platelet count and coagulation studies closely

**Prognosis:**

* HIT can be a life-threatening condition if not treated promptly and effectively
* The patient's prognosis is guarded, but prompt treatment can improve outcomes

**Follow-up:**

* Monitor the patient's platelet count and coagulation studies closely
* Consider repeating laboratory tests to confirm the diagnosis
* Follow up with the patient's primary care physician and cardiologist to ensure that the patient is receiving appropriate care.","Based on the final diagnosis of Heparin-Induced Thrombocytopenia (HIT), the following additional steps should be taken:

**Immediate steps:**

1. **Discontinue heparin and any other anticoagulant medications**: Immediately discontinue heparin and any other anticoagulant medications that the patient is receiving.
2. **Administer platelet transfusions as needed**: Administer platelet transfusions as needed to help stabilize the patient's platelet count.
3. **Monitor the patient's platelet count and coagulation studies closely**: Monitor the patient's platelet count and coagulation studies closely to ensure that the patient's condition is improving.

**Laboratory tests:**

1. **Repeat platelet count and coagulation studies**: Repeat platelet count and coagulation studies to confirm the diagnosis and monitor the patient's response to treatment.
2. **Perform a HIT antibody test**: Perform a HIT antibody test to confirm the presence of HIT antibodies.
3. **Monitor for thrombosis**: Monitor the patient for signs of thrombosis, such as new or worsening symptoms of deep vein thrombosis or pulmonary embolism.

**Clinical management:**

1. **Manage pain and discomfort**: Manage the patient's pain and discomfort with analgesics and other medications as needed.
2. **Monitor for signs of bleeding**: Monitor the patient for signs of bleeding, such as bruising or bleeding gums.
3. **Consider alternative anticoagulant medications**: Consider alternative anticoagulant medications, such as argatroban or bivalirudin, to prevent further thrombosis.

**Follow-up:**

1. **Follow up with the patient's primary care physician and cardiologist**: Follow up with the patient's primary care physician and cardiologist to ensure that the patient is receiving appropriate care.
2. **Monitor the patient's platelet count and coagulation studies closely**: Monitor the patient's platelet count and coagulation studies closely to ensure that the patient's condition is improving.
3. **Consider long-term anticoagulation therapy**: Consider long-term anticoagulation therapy to prevent further thrombosis.

**Patient education:**

1. **Educate the patient about HIT**: Educate the patient about HIT, its symptoms, and its treatment.
2. **Educate the patient about the importance of monitoring**: Educate the patient about the importance of monitoring their platelet count and coagulation studies closely.
3. **Educate the patient about the risks of bleeding**: Educate the patient about the risks of bleeding and the importance of reporting any signs of bleeding to their healthcare provider.

By taking these additional steps, the patient's condition can be managed effectively, and the risk of complications can be minimized.","{""Score"":1,""Rationale"":""Only 'Cholesterol embolism' matches a concept in the rubric; the other two diagnoses are not listed in the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes Cholesterol embolism, matching one of the three rubric items, but does not mention Acute interstitial nephritis or Peripheral arterial disease, so only 2 of the 6 possible points are earned.""}","{""Score"":0,""Rationale"":""The answer does not include any of the concepts or reasons listed in the high‑scoring example; it discusses different diagnoses and unrelated points, so no points are awarded.""}","{""Score"":0,""Rationale"":""The student's answer was Heparin-Induced Thrombocytopenia, which does not match the required answer 'Cholesterol embolism' as specified in the rubric.""}","{""Score"":0,""Rationale"":""The student's answer does not mention any of the required concepts from the rubric (arterial ultrasounds of lower extremities/ABI, urine analysis for casts/eosinophils with nephrology consult, or renal biopsy). Therefore no points are awarded.""}",3.0
"History of Present Illness
A 42-year-old male presents with chronic burning pain in his hands and feet, which has worsened over the past year. He has frequent episodes of abdominal cramping and diarrhea. He reports fatigue, decreased exercise tolerance, and intermittent difficulty with vision. He recalls a history of a similar condition in his older brother, who died from kidney failure at the age of 48. 

Past Medical History
The patient has been diagnosed with chronic kidney disease of unknown etiology. He also has a history of hearing loss and occasional headaches. There is a history of diabetes and hypertension. 

Physical Examination
VITALS: BP 150/90 mmHg, pulse 82/min, temperature 98.6°F. 
GEN: Thin, mildly fatigued. 
HEENT: Corneal opacities visible on slit lamp examination. 
CARDIAC: No murmurs or gallops. 
PULM: Clear to auscultation bilaterally. 
ABD: Non-tender, hepatosplenomegaly noted. 
EXT: Angiokeratomas on the lower abdomen and upper thighs. 
SKIN: No significant rashes. 

Laboratory Results
Serum creatinine is elevated at 2.8 mg/dL. Urinalysis shows 3+ proteinuria with no red blood cells. Alpha-galactosidase A activity in plasma is significantly reduced.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Fabry Disease**: This is a genetic disorder caused by a deficiency of the enzyme alpha-galactosidase A, which leads to the accumulation of globotriaosylceramide (Gb3) in various tissues, including the kidneys, heart, and nervous system. The patient's reduced alpha-galactosidase A activity in plasma and the presence of angiokeratomas (small, red or purple spots on the skin) are consistent with Fabry disease. The patient's symptoms, including chronic burning pain in the hands and feet, abdominal cramping, diarrhea, fatigue, and vision difficulties, are also typical of Fabry disease.

2. **Alport Syndrome**: This is a genetic disorder that affects the type IV collagen in the kidneys, ears, and eyes. The patient's history of chronic kidney disease, hearing loss, and corneal opacities are consistent with Alport syndrome. However, the patient's reduced alpha-galactosidase A activity in plasma is not typical of Alport syndrome.

3. **Nephropathic Cystinosis**: This is a rare genetic disorder caused by a deficiency of the enzyme cystinosin, which leads to the accumulation of cystine in the kidneys and other tissues. The patient's symptoms, including chronic kidney disease, abdominal cramping, diarrhea, and fatigue, are consistent with nephropathic cystinosis. However, the patient's reduced alpha-galactosidase A activity in plasma is not typical of nephropathic cystinosis.

It's worth noting that the patient's family history of a similar condition in his older brother, who died from kidney failure at the age of 48, suggests a possible genetic component to the patient's condition.","Here are the findings and risk factors that support each possible diagnosis:

**Fabry Disease**

1. **Reduced alpha-galactosidase A activity**: The patient's significantly reduced alpha-galactosidase A activity in plasma is a key diagnostic finding for Fabry disease.
2. **Angiokeratomas**: The presence of angiokeratomas on the lower abdomen and upper thighs is a characteristic skin lesion associated with Fabry disease.
3. **Chronic kidney disease**: Fabry disease can cause progressive kidney damage, leading to chronic kidney disease and end-stage renal disease.
4. **Hearing loss**: Hearing loss is a common complication of Fabry disease, particularly in the high-frequency range.
5. **Corneal opacities**: Corneal opacities are a common finding in Fabry disease, which can lead to vision difficulties.
6. **Family history**: The patient's family history of a similar condition in his older brother, who died from kidney failure at the age of 48, suggests a possible genetic component to the patient's condition.

**Alport Syndrome**

1. **Chronic kidney disease**: Alport syndrome is a genetic disorder that affects the kidneys, leading to chronic kidney disease and end-stage renal disease.
2. **Hearing loss**: Hearing loss is a common complication of Alport syndrome, particularly in the high-frequency range.
3. **Corneal opacities**: Corneal opacities are a characteristic finding in Alport syndrome, which can lead to vision difficulties.
4. **Family history**: The patient's family history of a similar condition in his older brother, who died from kidney failure at the age of 48, suggests a possible genetic component to the patient's condition.
5. **Genetic testing**: Genetic testing for Alport syndrome can confirm the diagnosis by identifying mutations in the COL4A3, COL4A4, or COL4A5 genes.

**Nephropathic Cystinosis**

1. **Chronic kidney disease**: Nephropathic cystinosis is a genetic disorder that affects the kidneys, leading to chronic kidney disease and end-stage renal disease.
2. **Abdominal cramping and diarrhea**: These symptoms are common in nephropathic cystinosis, which can be caused by the accumulation of cystine in the kidneys and other tissues.
3. **Fatigue**: Fatigue is a common symptom of nephropathic cystinosis, which can be caused by the accumulation of cystine in the kidneys and other tissues.
4. **Corneal opacities**: Corneal opacities are a characteristic finding in nephropathic cystinosis, which can lead to vision difficulties.
5. **Genetic testing**: Genetic testing for nephropathic cystinosis can confirm the diagnosis by identifying mutations in the CTNS gene.

It's worth noting that the patient's reduced alpha-galactosidase A activity in plasma and the presence of angiokeratomas are not typical of Alport syndrome or nephropathic cystinosis, making Fabry disease a more likely diagnosis.","Here are the findings that oppose each possible diagnosis:

**Fabry Disease**

1. **Lack of specific Fabry disease-related symptoms**: While the patient has chronic kidney disease, hearing loss, and corneal opacities, these symptoms are not specific to Fabry disease and can be found in other conditions.
2. **No mention of gastrointestinal symptoms**: Fabry disease can cause gastrointestinal symptoms such as abdominal pain, nausea, and vomiting, but these symptoms are not mentioned in the patient's history.
3. **No mention of cardiac symptoms**: Fabry disease can cause cardiac symptoms such as chest pain, shortness of breath, and arrhythmias, but these symptoms are not mentioned in the patient's history.
4. **Normal blood pressure**: While the patient has hypertension, Fabry disease can cause orthostatic hypotension, which is not mentioned in the patient's history.
5. **No mention of neuropathic pain**: Fabry disease can cause neuropathic pain, which is not mentioned in the patient's history.

**Alport Syndrome**

1. **No mention of hematuria**: Alport syndrome is characterized by hematuria (blood in the urine), which is not mentioned in the patient's history.
2. **No mention of proteinuria**: While the patient has proteinuria, Alport syndrome is typically characterized by hematuria and not proteinuria.
3. **No mention of hearing loss in the high-frequency range**: Alport syndrome typically causes hearing loss in the high-frequency range, but the patient's hearing loss is not specified.
4. **No mention of ocular abnormalities**: Alport syndrome can cause ocular abnormalities such as cataracts, glaucoma, and retinal detachment, but these are not mentioned in the patient's history.
5. **No family history of Alport syndrome**: Alport syndrome is typically inherited in an X-linked pattern, and a family history of the condition would be expected.

**Nephropathic Cystinosis**

1. **No mention of cystine crystals in the urine**: Nephropathic cystinosis is characterized by the presence of cystine crystals in the urine, which is not mentioned in the patient's history.
2. **No mention of liver disease**: Nephropathic cystinosis can cause liver disease, which is not mentioned in the patient's history.
3. **No mention of hypokalemia**: Nephropathic cystinosis can cause hypokalemia (low potassium levels), which is not mentioned in the patient's history.
4. **No mention of metabolic acidosis**: Nephropathic cystinosis can cause metabolic acidosis, which is not mentioned in the patient's history.
5. **No family history of nephropathic cystinosis**: Nephropathic cystinosis is typically inherited in an autosomal recessive pattern, and a family history of the condition would be expected.

These findings suggest that while each diagnosis is possible, there are some inconsistencies and missing information that make each diagnosis less likely.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Fabry Disease**

The patient's significantly reduced alpha-galactosidase A activity in plasma, the presence of angiokeratomas, chronic kidney disease, hearing loss, and corneal opacities are all consistent with Fabry disease. While there are some inconsistencies and missing information, such as the lack of specific Fabry disease-related symptoms and the absence of cardiac symptoms, the overall evidence suggests that Fabry disease is the most likely diagnosis.

**Supporting evidence:**

* Reduced alpha-galactosidase A activity in plasma
* Presence of angiokeratomas
* Chronic kidney disease
* Hearing loss
* Corneal opacities
* Family history of a similar condition in the patient's older brother

**Opposing evidence:**

* Lack of specific Fabry disease-related symptoms
* No mention of gastrointestinal symptoms
* No mention of cardiac symptoms
* Normal blood pressure
* No mention of neuropathic pain

**Differential diagnosis:**

* Alport syndrome: While Alport syndrome can cause chronic kidney disease, hearing loss, and corneal opacities, the patient's reduced alpha-galactosidase A activity in plasma and the presence of angiokeratomas are not typical of Alport syndrome.
* Nephropathic cystinosis: While nephropathic cystinosis can cause chronic kidney disease and corneal opacities, the patient's reduced alpha-galactosidase A activity in plasma and the presence of angiokeratomas are not typical of nephropathic cystinosis.

**Management:**

* Enzyme replacement therapy (ERT) with alpha-galactosidase A to reduce the accumulation of globotriaosylceramide (Gb3) in tissues
* Management of chronic kidney disease with dialysis or kidney transplantation as needed
* Management of hearing loss with hearing aids or cochlear implants as needed
* Management of corneal opacities with corneal transplantation as needed

**Prognosis:**

* With ERT, patients with Fabry disease can experience improved quality of life and reduced symptoms
* However, the disease is progressive, and patients may still experience complications such as chronic kidney disease, hearing loss, and corneal opacities.","Based on the final diagnosis of Fabry disease, the following additional steps should be taken:

**Initial Steps:**

1. **Confirm the diagnosis**: Confirm the diagnosis of Fabry disease through genetic testing to identify the specific mutation in the GLA gene.
2. **Enzyme replacement therapy (ERT)**: Start ERT with alpha-galactosidase A to reduce the accumulation of globotriaosylceramide (Gb3) in tissues.
3. **Monitor kidney function**: Regularly monitor kidney function to assess the effectiveness of ERT and to detect any potential kidney damage.
4. **Monitor hearing**: Regularly monitor hearing to assess the effectiveness of ERT and to detect any potential hearing loss.
5. **Monitor corneal opacities**: Regularly monitor corneal opacities to assess the effectiveness of ERT and to detect any potential corneal damage.

**Long-term Management:**

1. **Regular follow-up appointments**: Schedule regular follow-up appointments with the patient's primary care physician and specialists to monitor the patient's condition and adjust treatment as needed.
2. **Dietary modifications**: Encourage the patient to make dietary modifications to reduce the intake of galactose-containing foods, which can exacerbate the symptoms of Fabry disease.
3. **Exercise and physical activity**: Encourage the patient to engage in regular exercise and physical activity to improve overall health and well-being.
4. **Pain management**: Develop a pain management plan to help the patient manage chronic pain associated with Fabry disease.
5. **Psychological support**: Provide psychological support to the patient and their family to help them cope with the diagnosis and manage the emotional impact of the disease.

**Genetic Counseling:**

1. **Genetic testing**: Offer genetic testing to the patient's family members to identify carriers of the GLA gene mutation.
2. **Genetic counseling**: Provide genetic counseling to the patient's family members to discuss the risks and benefits of genetic testing and to help them make informed decisions about their reproductive options.

**Research and Clinical Trials:**

1. **Participate in clinical trials**: Encourage the patient to participate in clinical trials to help advance the treatment of Fabry disease.
2. **Stay up-to-date with research**: Stay up-to-date with the latest research on Fabry disease and its treatment options to provide the patient with the best possible care.

**Patient Education:**

1. **Patient education materials**: Provide the patient with patient education materials to help them understand their condition and its treatment options.
2. **Support groups**: Encourage the patient to join a support group to connect with others who have Fabry disease and to share their experiences and advice.
3. **Online resources**: Provide the patient with online resources to help them stay informed about their condition and its treatment options.","{
  ""Score"": 2,
  ""Rationale"": ""The answer includes Fabry Disease (matches rubric) and mentions Alport Syndrome with chronic kidney disease, which satisfies the CKD secondary to Alport requirement. It does not include the diabetes-related complications (diabetic nephropathy and neuropathy) required for the third point, and the third diagnosis (Nephropathic Cystinosis) is not in the rubric.""
}","{""Score"":4,""Rationale"":""The answer includes multiple concepts that match the Fabry Disease and Alport Syndrome entries in the rubric (e.g., reduced alpha‑galactosidase A activity, angiokeratomas, corneal opacities, family history, hearing loss). It does not provide the rubric‑listed concepts for Diabetic Related Complications or Polyarteritis Nodosa, so no points are awarded for those. Each matched diagnosis is worth 2 points, giving a total of 4 out of 6.""}","{""Score"":2,""Rationale"":""The answer only matches one rubric concept: it notes the absence of hematuria for Alport Syndrome, which aligns with the rubric's opposing finding. It fails to provide the required opposing findings for Fabry Disease, Diabetes-related complications, or Polyarteritis Nodosa, and includes unrelated diagnoses, so only 2 of the possible 6 points are earned.""}","{""Score"":2,""Rationale"":""Student correctly identified Fabry Disease and provided supporting clinical features matching the high‑scoring example (reduced alpha‑galactosidase A activity, angiokeratomas, corneal opacities, family history).""}","{""Score"":6,""Rationale"":""The answer includes all three required concepts from the rubric: genetic testing to confirm Fabry disease, initiation of enzyme replacement therapy, and monitoring of renal/kidney function. Each concept earns 2 points, totaling 6 points.""}",16.0
"History of Present Illness
A 55-year-old female presents with a 3-month history of progressive difficulty swallowing, drooping of her eyelids, and muscle weakness. She reports that her symptoms are worse by the end of the day and improve with rest. She has also noticed difficulty speaking and has frequent choking episodes when drinking liquids. There is no associated pain, and she denies any other systemic symptoms.

  Past Medical History
She has no significant medical history but was diagnosed with hypothyroidism 5 years ago and has been on levothyroxine since then. Family history is unremarkable.

  Physical Examination
VITALS: BP 130/80 mmHg, pulse 75/min, temperature 98.7°F. 
GEN: Well-appearing, no distress. 
HEENT: Ptosis noted in both eyelids, worse on the right side. 
PULM: Clear to auscultation bilaterally. 
NEURO: Proximal muscle weakness
EXT: No edema

  Laboratory Results
Acetylcholine receptor antibodies are positive. Serum creatine kinase (CK) is normal.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Myasthenia Gravis (MG)**: This is an autoimmune disease characterized by weakness and rapid fatigue of the muscles under voluntary control. The presence of ptosis (drooping eyelids), muscle weakness, and improvement of symptoms with rest are classic symptoms of MG. The positive acetylcholine receptor antibodies further support this diagnosis.

2. **Lambert-Eaton Myasthenic Syndrome (LEMS)**: This is another autoimmune disease that affects the neuromuscular junction, similar to MG. However, LEMS typically presents with muscle weakness that worsens with activity and improves with rest, which is opposite to MG. The patient's symptoms could be consistent with LEMS, but the presence of ptosis and the specific laboratory results are more suggestive of MG.

3. **Muscular Dystrophy**: This is a group of genetic disorders that affect muscle strength and function. While muscular dystrophy can present with muscle weakness, the patient's symptoms of ptosis, improvement with rest, and positive acetylcholine receptor antibodies are not typical of muscular dystrophy.

However, Myasthenia Gravis is the most likely diagnosis given the patient's symptoms and laboratory results.","Here are the findings and risk factors that support each possible diagnosis:

**Myasthenia Gravis (MG)**

1. **Symptoms**: The patient's symptoms of progressive difficulty swallowing, drooping of her eyelids (ptosis), muscle weakness, difficulty speaking, and frequent choking episodes when drinking liquids are classic symptoms of MG.
2. **Laboratory Results**: The positive acetylcholine receptor antibodies (AChR-Ab) are a hallmark of MG. These antibodies are directed against the acetylcholine receptors at the neuromuscular junction, leading to impaired neurotransmission and muscle weakness.
3. **Family History**: While there is no family history of MG, it is worth noting that MG can occur in individuals without a family history.
4. **Hypothyroidism**: The patient has a history of hypothyroidism, which is a common comorbidity with MG. Some studies suggest that hypothyroidism may be a risk factor for developing MG.
5. **Age**: The patient is 55 years old, which is within the typical age range for MG diagnosis.

**Lambert-Eaton Myasthenic Syndrome (LEMS)**

1. **Symptoms**: While the patient's symptoms of muscle weakness and improvement with rest could be consistent with LEMS, the presence of ptosis and the specific laboratory results are more suggestive of MG.
2. **Laboratory Results**: LEMS is typically associated with low levels of acetylcholine receptor antibodies, which is not the case in this patient.
3. **Cancer Association**: LEMS is often associated with small cell lung cancer, which is not mentioned in the patient's history.
4. **Age**: LEMS typically presents in older adults, which is consistent with the patient's age.

**Muscular Dystrophy**

1. **Genetic Predisposition**: Muscular dystrophy is a group of genetic disorders that affect muscle strength and function. However, there is no mention of a family history of muscular dystrophy or a known genetic mutation.
2. **Symptoms**: While the patient's symptoms of muscle weakness could be consistent with muscular dystrophy, the presence of ptosis and the specific laboratory results are not typical of muscular dystrophy.
3. **Laboratory Results**: The normal serum creatine kinase (CK) level is not consistent with muscular dystrophy, which typically presents with elevated CK levels.
4. **Age**: Muscular dystrophy typically presents in childhood or adolescence, which is not consistent with the patient's age.

Overall, the findings and risk factors support a diagnosis of Myasthenia Gravis (MG) in this patient.","Here are the findings that oppose each possible diagnosis:

**Myasthenia Gravis (MG)**

1. **Normal Serum Creatine Kinase (CK) Level**: While a normal CK level is not uncommon in MG, it is not typical for MG patients to have a completely normal CK level. Elevated CK levels are often seen in MG patients, especially those with significant muscle weakness.
2. **Absence of Ocular Symptoms**: While ptosis is a common symptom of MG, some patients may not experience ocular symptoms at all. However, the patient's symptoms of difficulty swallowing and speaking are more typical of generalized MG rather than ocular MG.
3. **No Mention of Thymoma**: Thymoma is a type of tumor that is often associated with MG. While not all MG patients have thymoma, its absence is not typical in patients with generalized MG.
4. **No Mention of Muscle Fatigue with Repetitive Movements**: Muscle fatigue with repetitive movements is a common symptom of MG. The patient's symptoms of muscle weakness and improvement with rest are more typical of MG, but the absence of muscle fatigue with repetitive movements is not typical.

**Lambert-Eaton Myasthenic Syndrome (LEMS)**

1. **Positive Acetylcholine Receptor Antibodies**: LEMS is typically associated with low levels of acetylcholine receptor antibodies, which is not the case in this patient. The presence of positive AChR-Ab is more suggestive of MG.
2. **Absence of Small Cell Lung Cancer**: LEMS is often associated with small cell lung cancer. The patient's history does not mention any cancer diagnosis, which is not typical for LEMS.
3. **No Mention of Autonomic Symptoms**: Autonomic symptoms such as dry mouth, constipation, and orthostatic hypotension are common in LEMS. The patient's symptoms do not mention any autonomic symptoms.
4. **No Mention of Muscle Weakness in the Extremities**: LEMS typically presents with muscle weakness in the extremities, which is not mentioned in the patient's history.

**Muscular Dystrophy**

1. **Normal Serum Creatine Kinase (CK) Level**: Muscular dystrophy typically presents with elevated CK levels, which is not the case in this patient.
2. **Absence of Family History**: Muscular dystrophy is a genetic disorder that often has a family history. The patient's family history is unremarkable, which is not typical for muscular dystrophy.
3. **No Mention of Muscle Weakness in the Proximal Muscles**: Muscular dystrophy typically presents with muscle weakness in the proximal muscles, which is not mentioned in the patient's history.
4. **No Mention of Muscle Atrophy**: Muscle atrophy is a common feature of muscular dystrophy, which is not mentioned in the patient's history.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Myasthenia Gravis (MG)**

The patient's symptoms of progressive difficulty swallowing, drooping of her eyelids (ptosis), muscle weakness, difficulty speaking, and frequent choking episodes when drinking liquids are classic symptoms of MG. The positive acetylcholine receptor antibodies (AChR-Ab) are a hallmark of MG, and the patient's age and lack of family history are consistent with MG.

While the patient's normal serum creatine kinase (CK) level and absence of ocular symptoms are not typical for MG, they do not rule out the diagnosis. The patient's symptoms of muscle weakness and improvement with rest are more typical of MG, and the absence of muscle fatigue with repetitive movements is not a strong contraindication.

In contrast, the patient's symptoms and laboratory results do not strongly support a diagnosis of Lambert-Eaton Myasthenic Syndrome (LEMS) or Muscular Dystrophy. The patient's symptoms of muscle weakness and improvement with rest are more typical of MG, and the absence of small cell lung cancer and autonomic symptoms makes LEMS less likely. The patient's normal CK level and lack of family history also make Muscular Dystrophy less likely.

Therefore, based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the final diagnosis of **Myasthenia Gravis (MG)**.

**Treatment Plan**

The patient will be started on pyridostigmine, a cholinesterase inhibitor that will help to improve muscle strength and reduce symptoms. The patient will also be referred to a neurologist for further evaluation and management. The patient will be monitored for any signs of thymoma or other complications, and the patient will be educated on the importance of adhering to the treatment plan and monitoring for any changes in symptoms.

**Follow-up**

The patient will be seen in follow-up in 2 weeks to assess the effectiveness of the treatment and to make any necessary adjustments. The patient will also be seen in follow-up every 3 months to monitor for any changes in symptoms and to adjust the treatment plan as needed.","Based on the final diagnosis of Myasthenia Gravis (MG), the following additional steps should be taken:

**Imaging Studies**

1. **Chest X-ray**: A chest X-ray should be performed to rule out thymoma, a type of tumor that is often associated with MG.
2. **Computed Tomography (CT) Scan**: A CT scan of the chest and abdomen should be performed to rule out thymoma and to evaluate the patient's overall anatomy.

**Electrophysiological Studies**

1. **Electromyography (EMG)**: An EMG should be performed to evaluate the patient's muscle function and to rule out other conditions that may be causing the patient's symptoms.
2. **Nerve Conduction Studies (NCS)**: NCS should be performed to evaluate the patient's nerve function and to rule out other conditions that may be causing the patient's symptoms.

**Thymectomy**

1. **Thymectomy**: A thymectomy may be considered if the patient has a thymoma or if the patient's symptoms are not adequately controlled with medication.
2. **Video-Assisted Thoracic Surgery (VATS)**: VATS may be used to perform the thymectomy, which is a minimally invasive surgical procedure.

**Medication Management**

1. **Pyridostigmine**: The patient should continue to take pyridostigmine, a cholinesterase inhibitor that will help to improve muscle strength and reduce symptoms.
2. **Mestinon**: Mestinon, another cholinesterase inhibitor, may be added to the patient's treatment plan if the patient's symptoms are not adequately controlled with pyridostigmine.
3. **Steroids**: Steroids may be added to the patient's treatment plan if the patient's symptoms are not adequately controlled with medication.

**Monitoring**

1. **Follow-up Appointments**: The patient should be seen in follow-up appointments every 2-3 months to monitor for any changes in symptoms and to adjust the treatment plan as needed.
2. **Blood Tests**: The patient should have regular blood tests to monitor for any changes in liver function, kidney function, and electrolyte levels.
3. **Pulmonary Function Tests**: The patient should have regular pulmonary function tests to monitor for any changes in lung function.

**Patient Education**

1. **Medication Adherence**: The patient should be educated on the importance of adhering to the treatment plan and taking medication as directed.
2. **Symptom Management**: The patient should be educated on how to manage symptoms, such as muscle weakness and fatigue.
3. **Lifestyle Modifications**: The patient should be educated on lifestyle modifications, such as getting regular exercise and avoiding heavy lifting, to help manage symptoms.

**Referral to a Neurologist**

The patient should be referred to a neurologist for further evaluation and management. The neurologist can provide additional guidance on the treatment plan and can help to monitor the patient's progress.","{""Score"":2,""Rationale"":""The answer includes Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome, which match two of the three required concepts. The third listed condition, Muscular Dystrophy, does not match the required Hypothyroid Myopathy, so only two points are awarded.""}","{
  ""Score"": 4,
  ""Rationale"": ""The answer includes correct concepts for Myasthenia Gravis (symptoms and positive AChR antibodies) and Lambert-Eaton Myasthenic Syndrome (symptoms and improvement with activity), matching items in the rubric, earning 2 points each. It does not mention Hypothyroid Myopathy at all, so no points for that category.""
}","{""Score"":0,""Rationale"":""The student's opposing findings for Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, and the third condition do not match any of the specific opposing findings listed in the rubric's high scoring example, resulting in zero points.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Myasthenia Gravis, cites ptosis, bulbar weakness, fatigue improving with rest, and positive acetylcholine receptor antibodies, matching the concepts in the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes a CT scan of the chest, matching the first rubric item (CT scan/MRI to rule out thymoma). It does not mention the Edrophonium (Tensilon) test or assessment of thyroid function, so only 2 of the possible 6 points are earned.""}",10.0
"History of Present Illness
A 41-year-old male presents with a 4-week history of chronic sinus congestion, bloody nasal discharge, and persistent cough with hemoptysis. He also complains of joint pain and swelling in both knees and ankles. He reports unintentional weight loss of 8 kg over the last 2 months. He denies any recent trauma, travel, or exposure to sick contacts.

  Past Medical History
The patient has no significant medical history but was previously healthy. He has no known drug allergies and does not smoke or drink alcohol.

  Physical Examination
VITALS: BP 120/78 mmHg, pulse 88/min, temperature 99.2°F. 
GEN: Well-appearing but fatigued. 
HEENT: Nasal mucosal ulcerations, bloody discharge from both nostrils. 
PULM: Bilateral rales in the lungs. 
ABD: Soft, non-tender. 
EXT: Swelling in both knees and ankles, with mild erythema. 
SKIN: No rashes.

  Laboratory Results
WBC count is 12.8 x 103/μL, with a mild left shift. ESR is elevated at 75 mm/h. Serum creatinine is 1.5 mg/dL, and urinalysis shows 1+ proteinuria with RBC casts. c-ANCA is positive. Chest CT shows multiple nodular lung infiltrates and cavities.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Granulomatosis with Polyangiitis (GPA)**: Also known as Wegener's granulomatosis, GPA is a rare autoimmune disorder characterized by inflammation of blood vessels (vasculitis) and the presence of c-ANCA (cytoplasmic anti-neutrophil cytoplasmic antibodies). The patient's symptoms, including chronic sinus congestion, bloody nasal discharge, joint pain, and hemoptysis, along with the presence of c-ANCA and lung infiltrates, are consistent with GPA.

2. **Microscopic Polyangiitis (MPA)**: MPA is another autoimmune disorder that causes inflammation of blood vessels and is often associated with p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies). However, the patient's c-ANCA positivity and the presence of lung cavities make GPA a more likely diagnosis. MPA can also cause similar symptoms, including kidney involvement and lung infiltrates.

3. **Eosinophilic Granulomatosis with Polyangiitis (EGPA)**: EGPA, formerly known as Churg-Strauss syndrome, is a rare autoimmune disorder characterized by the presence of eosinophils and vasculitis. The patient's symptoms, including chronic sinus congestion, joint pain, and lung infiltrates, could be consistent with EGPA. However, the presence of c-ANCA and the absence of eosinophilia in the laboratory results make GPA a more likely diagnosis.

It's essential to note that these diagnoses are not mutually exclusive, and the patient may have a combination of these conditions or another underlying cause for their symptoms. Further testing and evaluation are necessary to confirm the diagnosis.","Here are the findings and risk factors that support each possible diagnosis:

**Granulomatosis with Polyangiitis (GPA)**

1. **Symptoms**: The patient's symptoms, including chronic sinus congestion, bloody nasal discharge, joint pain, and hemoptysis, are consistent with GPA.
2. **c-ANCA positivity**: The presence of c-ANCA is a hallmark of GPA and is found in approximately 90% of patients with this condition.
3. **Lung infiltrates and cavities**: The chest CT findings of multiple nodular lung infiltrates and cavities are consistent with GPA, which often causes lung damage and cavitation.
4. **Kidney involvement**: The presence of proteinuria and RBC casts in the urinalysis suggests kidney involvement, which is common in GPA.
5. **Elevated ESR**: The elevated ESR is consistent with GPA, which often causes inflammation and tissue damage.

**Microscopic Polyangiitis (MPA)**

1. **Kidney involvement**: The presence of proteinuria and RBC casts in the urinalysis suggests kidney involvement, which is common in MPA.
2. **Lung infiltrates**: The chest CT findings of multiple nodular lung infiltrates are consistent with MPA, which often causes lung damage.
3. **Elevated ESR**: The elevated ESR is consistent with MPA, which often causes inflammation and tissue damage.
4. **Absence of c-ANCA**: The absence of c-ANCA and the presence of p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies) would be more consistent with MPA.

**Eosinophilic Granulomatosis with Polyangiitis (EGPA)**

1. **Chronic sinus congestion**: The patient's chronic sinus congestion is consistent with EGPA, which often causes sinusitis.
2. **Joint pain**: The patient's joint pain is consistent with EGPA, which often causes musculoskeletal symptoms.
3. **Lung infiltrates**: The chest CT findings of multiple nodular lung infiltrates are consistent with EGPA, which often causes lung damage.
4. **Elevated ESR**: The elevated ESR is consistent with EGPA, which often causes inflammation and tissue damage.
5. **Absence of c-ANCA**: The absence of c-ANCA and the presence of eosinophilia would be more consistent with EGPA.

However, the patient's c-ANCA positivity and the absence of eosinophilia in the laboratory results make GPA a more likely diagnosis.","Here are the findings that oppose each possible diagnosis:

**Granulomatosis with Polyangiitis (GPA)**

1. **Absence of eosinophilia**: GPA is often associated with eosinophilia, but the patient's laboratory results do not show eosinophilia.
2. **Lack of granulomatous inflammation**: GPA is characterized by granulomatous inflammation, but the patient's biopsy results are not mentioned, and the presence of granulomatous inflammation is not confirmed.
3. **No mention of asthma or allergic rhinitis**: GPA is often associated with asthma or allergic rhinitis, but the patient's medical history does not mention these conditions.
4. **Unusual age of onset**: GPA typically affects middle-aged adults, but the patient is 41 years old, which is slightly younger than the typical age of onset.
5. **No mention of skin involvement**: GPA can cause skin lesions, but the patient's physical examination does not mention any skin involvement.

**Microscopic Polyangiitis (MPA)**

1. **Presence of c-ANCA**: MPA is typically associated with p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies), but the patient's c-ANCA positivity is more consistent with GPA.
2. **Lack of renal involvement**: MPA often causes severe renal involvement, but the patient's urinalysis shows only mild proteinuria and RBC casts.
3. **No mention of gastrointestinal involvement**: MPA can cause gastrointestinal symptoms, but the patient's medical history does not mention any gastrointestinal issues.
4. **Unusual lung involvement**: MPA often causes diffuse alveolar hemorrhage, but the patient's chest CT shows multiple nodular lung infiltrates and cavities, which is more consistent with GPA.
5. **No mention of cardiac involvement**: MPA can cause cardiac involvement, but the patient's medical history does not mention any cardiac issues.

**Eosinophilic Granulomatosis with Polyangiitis (EGPA)**

1. **Presence of c-ANCA**: EGPA is typically associated with p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies), but the patient's c-ANCA positivity is more consistent with GPA.
2. **Absence of eosinophilia**: EGPA is characterized by eosinophilia, but the patient's laboratory results do not show eosinophilia.
3. **No mention of asthma or allergic rhinitis**: EGPA is often associated with asthma or allergic rhinitis, but the patient's medical history does not mention these conditions.
4. **Unusual lung involvement**: EGPA often causes diffuse alveolar hemorrhage, but the patient's chest CT shows multiple nodular lung infiltrates and cavities, which is more consistent with GPA.
5. **No mention of skin involvement**: EGPA can cause skin lesions, but the patient's physical examination does not mention any skin involvement.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Granulomatosis with Polyangiitis (GPA)**

The patient's symptoms, including chronic sinus congestion, bloody nasal discharge, joint pain, and hemoptysis, are consistent with GPA. The presence of c-ANCA positivity is a hallmark of GPA, and the chest CT findings of multiple nodular lung infiltrates and cavities are also consistent with this diagnosis. The patient's kidney involvement, as evidenced by proteinuria and RBC casts in the urinalysis, is also consistent with GPA.

While the patient's absence of eosinophilia and lack of granulomatous inflammation on biopsy are not typical of GPA, these findings are not sufficient to rule out this diagnosis. The patient's age of 41 is slightly younger than the typical age of onset for GPA, but this is not uncommon.

In contrast, the patient's symptoms and laboratory results do not strongly support a diagnosis of Microscopic Polyangiitis (MPA) or Eosinophilic Granulomatosis with Polyangiitis (EGPA). The patient's c-ANCA positivity and lung involvement are more consistent with GPA than with MPA or EGPA.

Therefore, based on the available information, I would make a diagnosis of Granulomatosis with Polyangiitis (GPA).

**Treatment Plan**

The treatment plan for GPA typically involves a combination of immunosuppressive medications, including corticosteroids and cyclophosphamide. The patient may also require supportive care, such as oxygen therapy and pain management.

**Follow-up**

The patient should be followed closely to monitor for any signs of disease flare or treatment toxicity. Regular laboratory tests, including complete blood counts and renal function tests, should be performed to monitor the patient's response to treatment.

**Prognosis**

The prognosis for GPA is generally good with treatment, but the disease can be unpredictable and may require long-term management. The patient should be educated about the importance of adhering to their treatment regimen and attending regular follow-up appointments to monitor their disease.","Based on the diagnosis of Granulomatosis with Polyangiitis (GPA), the following additional steps should be taken:

**Biopsy**

A biopsy of the affected tissue, such as the nasal mucosa or lung tissue, should be performed to confirm the diagnosis and rule out other conditions. The biopsy results will help to determine the extent of the disease and guide treatment.

**Imaging Studies**

Imaging studies, such as a chest CT scan or MRI, should be performed to assess the extent of the disease and monitor the patient's response to treatment. These studies will help to identify any new or worsening lesions and guide treatment decisions.

**Laboratory Tests**

Regular laboratory tests, including complete blood counts, renal function tests, and liver function tests, should be performed to monitor the patient's response to treatment and detect any signs of disease flare or treatment toxicity.

**Treatment Optimization**

The patient's treatment regimen should be optimized to achieve the best possible outcome. This may involve adjusting the dose or type of medication, adding new medications, or switching to a different treatment approach.

**Supportive Care**

The patient should receive supportive care, such as oxygen therapy, pain management, and nutritional support, to manage symptoms and improve quality of life.

**Follow-up**

The patient should be followed closely to monitor for any signs of disease flare or treatment toxicity. Regular follow-up appointments should be scheduled to assess the patient's response to treatment and make any necessary adjustments.

**Patient Education**

The patient should be educated about the disease, its treatment, and its management. This will help the patient to understand their condition, manage their symptoms, and make informed decisions about their care.

**Referral to a Specialist**

The patient should be referred to a specialist, such as a rheumatologist or a pulmonologist, for further evaluation and management. This will ensure that the patient receives the best possible care and that their condition is managed by a healthcare professional with expertise in GPA.

**Genetic Testing**

Genetic testing may be considered to identify any genetic mutations that may be contributing to the patient's condition. This may help to guide treatment decisions and improve outcomes.

**Family Screening**

Family members of the patient should be screened for GPA to identify any potential carriers of the disease. This will help to prevent the disease from progressing and improve outcomes.

**Registry Participation**

The patient should be encouraged to participate in a registry or database to track their disease progression and treatment outcomes. This will help to improve our understanding of GPA and develop more effective treatments.

**Clinical Trials**

The patient should be considered for participation in clinical trials to evaluate new treatments for GPA. This will help to advance our understanding of the disease and develop more effective treatments.","{""Score"":1,""Rationale"":""Only Granulomatosis with Polyangiitis (GPA) matches an item in the rubric; Rheumatoid Arthritis and infectious causes are absent, and the other listed diagnoses are not in the rubric.""}","{""Score"":2,""Rationale"":""The answer correctly identifies GPA features matching the rubric (sinus congestion, bloody nasal discharge, hemoptysis, lung infiltrates, joint pain, proteinuria with RBC casts, c‑ANCA positivity, elevated ESR), earning 2 points. It does not mention Rheumatoid Arthritis or Infectious Causes, so no points for those sections.""}","{
  ""Score"": 0,
  ""Rationale"": ""The answer does not match any of the concepts or specific opposing findings listed in the rubric. It provides opposing points for GPA and introduces diagnoses (MPA, EGPA) not present in the rubric, and contradicts the rubric's statement of no opposing findings for GPA. Therefore, no points are awarded.""
}","{""Score"":2,""Rationale"":""Student correctly identified Granulomatosis with Polyangiitis (GPA) as the diagnosis, matching the high‑scoring example in the rubric.""}","{""Score"":2,""Rationale"":""The answer includes referral to a rheumatologist, matching rubric item 2 (2 points). It does not mention serial urine analysis or joint imaging, so no points for items 1 and 3.""}",7.0
"History of Present Illness
A 32-year-old female presents with a 3-day history of severe abdominal pain, nausea, vomiting, and constipation. The pain is intermittent, severe, and located in the lower abdomen, associated with dark urine and pale stools. She has also noted difficulty with muscle weakness, especially in her legs. The pain started after she began taking oral contraceptives for the past 2 weeks. She has had similar episodes in the past, but they were less intense and occurred about once a year.

  Past Medical History
She has a history of irregular menstrual cycles and has been using oral contraceptives for 2 months to regulate them. There is no significant family history of bleeding or liver disorders. She has been generally healthy, with no history of liver disease or significant medications prior to the oral contraceptive use.

  Physical Examination
VITALS: BP 120/75 mmHg, pulse 85/min, temperature 98.9°F. 
GEN: Appears in moderate distress, pale. 
CARDIAC: Regular rhythm, no murmurs. 
PULM: Clear to auscultation bilaterally. 
ABD: Diffuse tenderness to palpation in the lower abdomen with no rebound tenderness. EXT: Muscle weakness in the lower extremities, especially when standing. 
SKIN: No rashes, but urine is dark brown in color.

  Laboratory Results
Urine porphyrin levels are markedly elevated. Serum sodium is low at 130 mEq/L, and liver function tests are normal. Hemoglobin is 11.3 g/dL.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Acute Intermittent Porphyria (AIP)**: This is a genetic disorder that affects the production of heme, a vital molecule in the body. The symptoms of AIP, such as abdominal pain, muscle weakness, and dark urine, are consistent with the patient's presentation. The markedly elevated urine porphyrin levels also support this diagnosis.

2. **Hepatic Porphyria**: This is another type of porphyria that is caused by a deficiency of the enzyme uroporphyrinogen decarboxylase. The symptoms of hepatic porphyria, such as abdominal pain, muscle weakness, and dark urine, are similar to those of AIP. However, hepatic porphyria is often associated with liver dysfunction, which is not evident in this patient's case.

3. **Lead Poisoning**: Although less likely, lead poisoning can cause abdominal pain, constipation, and muscle weakness. The dark urine and pale stools may also be seen in lead poisoning. However, the markedly elevated urine porphyrin levels and the patient's history of taking oral contraceptives make lead poisoning a less likely diagnosis.

It's worth noting that the patient's history of taking oral contraceptives may have triggered an episode of porphyria, as certain medications can precipitate attacks in susceptible individuals.","Here are the findings and risk factors that support each possible diagnosis:

**Acute Intermittent Porphyria (AIP)**

1. **Family History**: Although the patient does not have a significant family history of bleeding or liver disorders, AIP is an autosomal dominant disorder, meaning that a single copy of the mutated gene is sufficient to cause the condition. The patient's symptoms may be triggered by various factors, including hormonal changes, which could be related to her use of oral contraceptives.
2. **Symptoms**: The patient's symptoms, such as abdominal pain, muscle weakness, and dark urine, are classic for AIP. The intermittent nature of the pain and the presence of muscle weakness, especially in the legs, are also consistent with this diagnosis.
3. **Laboratory Results**: The markedly elevated urine porphyrin levels are a key diagnostic finding for AIP. The normal liver function tests and low serum sodium level are also consistent with this diagnosis.
4. **Triggering Factors**: The patient's use of oral contraceptives may have triggered an episode of AIP. Certain medications, including hormonal contraceptives, can precipitate attacks in susceptible individuals.

**Hepatic Porphyria**

1. **Liver Dysfunction**: Although the patient's liver function tests are normal, hepatic porphyria is often associated with liver dysfunction, including elevated liver enzymes and bilirubin levels. The absence of liver dysfunction in this case makes this diagnosis less likely.
2. **Symptoms**: The patient's symptoms, such as abdominal pain and muscle weakness, are similar to those of AIP. However, the presence of liver dysfunction is typically a key feature of hepatic porphyria.
3. **Laboratory Results**: The markedly elevated urine porphyrin levels are consistent with both AIP and hepatic porphyria. However, the normal liver function tests make this diagnosis less likely.

**Lead Poisoning**

1. **Exposure History**: There is no mention of lead exposure in the patient's history, which makes this diagnosis less likely.
2. **Symptoms**: The patient's symptoms, such as abdominal pain, constipation, and muscle weakness, are similar to those of lead poisoning. However, the presence of dark urine and pale stools is more typical of porphyria.
3. **Laboratory Results**: The markedly elevated urine porphyrin levels are not consistent with lead poisoning. Lead poisoning is typically associated with elevated lead levels in the blood and urine.
4. **Risk Factors**: The patient's use of oral contraceptives does not increase her risk of lead poisoning.","Here are the findings that oppose each possible diagnosis:

**Acute Intermittent Porphyria (AIP)**

1. **Liver Dysfunction**: Although the patient's liver function tests are normal, AIP is often associated with liver dysfunction, including elevated liver enzymes and bilirubin levels. The absence of liver dysfunction in this case makes this diagnosis less likely.
2. **Severe Anemia**: AIP is often associated with severe anemia, which is not evident in this case (hemoglobin is 11.3 g/dL, which is slightly below the normal range but not severely low).
3. **Neurological Symptoms**: While muscle weakness is a symptom of AIP, the patient's neurological examination is not mentioned as being abnormal. AIP can also cause neurological symptoms such as seizures, psychosis, and neuropathy, which are not mentioned in this case.
4. **Family History**: Although AIP is an autosomal dominant disorder, the patient's family history is not mentioned as being positive for AIP or other porphyrias.

**Hepatic Porphyria**

1. **Liver Dysfunction**: Hepatic porphyria is often associated with liver dysfunction, including elevated liver enzymes and bilirubin levels. The absence of liver dysfunction in this case makes this diagnosis less likely.
2. **Severe Abdominal Pain**: Hepatic porphyria is often associated with severe abdominal pain, which is not mentioned as being a feature of this patient's case.
3. **Neurological Symptoms**: While muscle weakness is a symptom of hepatic porphyria, the patient's neurological examination is not mentioned as being abnormal. Hepatic porphyria can also cause neurological symptoms such as seizures, psychosis, and neuropathy, which are not mentioned in this case.
4. **Urine Porphyrin Levels**: While the patient's urine porphyrin levels are markedly elevated, the pattern of porphyrin elevation is not typical of hepatic porphyria.

**Lead Poisoning**

1. **Exposure History**: There is no mention of lead exposure in the patient's history, which makes this diagnosis less likely.
2. **Severe Abdominal Pain**: Lead poisoning is often associated with severe abdominal pain, which is not mentioned as being a feature of this patient's case.
3. **Neurological Symptoms**: While muscle weakness is a symptom of lead poisoning, the patient's neurological examination is not mentioned as being abnormal. Lead poisoning can also cause neurological symptoms such as seizures, psychosis, and neuropathy, which are not mentioned in this case.
4. **Laboratory Results**: The patient's urine porphyrin levels are markedly elevated, which is not consistent with lead poisoning. Lead poisoning is typically associated with elevated lead levels in the blood and urine.","Based on the patient's symptoms, laboratory results, and the findings that support and oppose each possible diagnosis, I would make the following final diagnosis:

**Acute Intermittent Porphyria (AIP)**

The patient's symptoms, such as abdominal pain, muscle weakness, and dark urine, are classic for AIP. The markedly elevated urine porphyrin levels are a key diagnostic finding for AIP. While the patient's liver function tests are normal, AIP can occur in the absence of liver dysfunction. The patient's use of oral contraceptives may have triggered an episode of AIP, as certain medications can precipitate attacks in susceptible individuals.

The findings that oppose this diagnosis, such as the absence of liver dysfunction and severe anemia, are not sufficient to rule out AIP. The patient's symptoms and laboratory results are more consistent with AIP than with hepatic porphyria or lead poisoning.

**Treatment Plan**

The patient will require hospitalization for close monitoring and management of her symptoms. She will be started on intravenous fluids and pain management as needed. She will also be given a medication called hemin to help reduce the production of porphyrins and alleviate her symptoms.

**Follow-up**

The patient will require regular follow-up appointments to monitor her symptoms and laboratory results. She will also need to avoid certain medications that can precipitate attacks of AIP, such as oral contraceptives.

**Genetic Testing**

The patient's family members may benefit from genetic testing to determine if they are carriers of the mutated gene that causes AIP. This can help identify individuals who are at risk of developing AIP and allow for early intervention and management of symptoms.","Based on the final diagnosis of Acute Intermittent Porphyria (AIP), the following additional steps should be taken:

**Immediate Management**

1. **Intravenous Fluids**: Administer intravenous fluids to help manage the patient's symptoms and prevent dehydration.
2. **Pain Management**: Provide pain management as needed to alleviate the patient's abdominal pain and muscle weakness.
3. **Hemin Therapy**: Start hemin therapy to help reduce the production of porphyrins and alleviate the patient's symptoms.
4. **Monitoring**: Monitor the patient's vital signs, including blood pressure, pulse, and oxygen saturation, closely.

**Laboratory Tests**

1. **Repeat Urine Porphyrin Levels**: Repeat urine porphyrin levels to confirm the diagnosis and monitor the patient's response to treatment.
2. **Liver Function Tests**: Repeat liver function tests to monitor for any changes in liver function.
3. **Complete Blood Count (CBC)**: Perform a CBC to monitor for any changes in the patient's blood counts.
4. **Electrolyte Panel**: Perform an electrolyte panel to monitor for any changes in the patient's electrolyte levels.

**Genetic Testing**

1. **Family Members**: Offer genetic testing to the patient's family members to determine if they are carriers of the mutated gene that causes AIP.
2. **Genetic Counseling**: Provide genetic counseling to the patient and her family members to discuss the risks and benefits of genetic testing.

**Medication Management**

1. **Avoid Certain Medications**: Avoid prescribing certain medications that can precipitate attacks of AIP, such as oral contraceptives, barbiturates, and certain antidepressants.
2. **Monitor for Medication-Related Symptoms**: Monitor the patient for any medication-related symptoms, such as abdominal pain, muscle weakness, and dark urine.

**Follow-up Care**

1. **Regular Follow-up Appointments**: Schedule regular follow-up appointments to monitor the patient's symptoms and laboratory results.
2. **Long-term Management**: Develop a long-term management plan to help the patient manage her AIP symptoms and prevent future attacks.

**Patient Education**

1. **AIP Education**: Educate the patient about AIP, its symptoms, and its management.
2. **Medication Education**: Educate the patient about the medications that can precipitate attacks of AIP and the importance of avoiding them.
3. **Emergency Plan**: Develop an emergency plan with the patient to help her manage her symptoms in the event of a future attack.","{""Score"":0.5,""Rationale"":""The answer includes Acute Intermittent Porphyria (AIP), which matches one of the three required diagnoses in the rubric. The other two listed conditions (Hepatic Porphyria and Lead Poisoning) are not in the rubric, so only partial credit is awarded.""}","{""Score"":1,""Rationale"":""The answer includes Acute Intermittent Porphyria, which matches a concept in the high‑scoring example and earns a point. It does not mention Cholecystitis/Gallstones or Irritable Bowel Syndrome, and adds unrelated diagnoses (Hepatic Porphyria, Lead Poisoning) that are not in the rubric, so no additional points are awarded.""}","{
  ""Score"": 0,
  ""Rationale"": ""The student's answer lists opposing findings for AIP, hepatic porphyria, and lead poisoning, which does not match any of the concepts or statements presented in the high scoring example. Therefore, no points are awarded.""
}","{""Score"":14.5,""Rationale"":""Student correctly identified Acute Intermittent Porphyria (AIP) and cited abdominal pain, muscle weakness, dark urine, and elevated urine porphyrins, matching the high‑scoring example.""}","{""Score"":3,""Rationale"":""Student includes genetic testing, hemin (hematine) infusion, and avoidance of oral contraceptives, matching all three rubric items.""}",19.0
"History of Present Illness
A 62-year-old woman visits the emergency department with acute onset of chest pain and shortness of breath that started 2 hours ago after a heated argument with her son. She describes the pain as crushing and radiating to her left arm. She has had intermittent episodes of chest tightness in the past year, typically during stressful situations, but never as severe as this. She denies nausea, vomiting, or syncope.

  Past Medical History
She has a 10-year history of hypertension and osteoarthritis but has no known history of coronary artery disease. She is on lisinopril and acetaminophen. She has no family history of cardiac conditions or sudden death. She denies smoking or alcohol use.

  Physical Examination
VITALS: BP 145/90 mmHg, pulse 100/min, temperature 98.4°F. 
GEN: Mildly anxious, diaphoretic. 
CARDIAC: Tachycardic, no murmurs or gallops. 
PULM: Clear to auscultation bilaterally. 
ABD: Non-tender, no hepatosplenomegaly. 
EXT: No cyanosis or edema. 
SKIN: Warm and dry.

  Laboratory Results
Troponin I is elevated at 3.5 ng/mL. Serum brain natriuretic peptide (BNP) is 280 pg/mL. Electrocardiogram (ECG) shows ST-segment elevation in leads V2-V4. ",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the provided information, here are three possible diagnoses for the 62-year-old woman:

1. **Acute Myocardial Infarction (AMI)**: The patient's symptoms of crushing chest pain radiating to the left arm, elevated troponin I levels (3.5 ng/mL), and ST-segment elevation in leads V2-V4 on the ECG are consistent with an AMI, also known as a heart attack.

2. **Angina Pectoris**: Although the patient has had episodes of chest tightness in the past, the current episode is more severe and accompanied by elevated troponin I levels, which suggests a possible acute coronary syndrome. However, the lack of ST-segment elevation in all leads and the absence of other symptoms like nausea or syncope might suggest angina pectoris.

3. **Cardiac Stress-Induced Condition**: The patient's symptoms started after a heated argument, which suggests a possible stress-induced condition. The elevated BNP levels (280 pg/mL) and the patient's mildly anxious and diaphoretic state might support this diagnosis. However, the elevated troponin I levels and ST-segment elevation on the ECG are more indicative of an AMI.

It is essential to note that these diagnoses are not mutually exclusive, and the patient may have a combination of conditions. Further evaluation and testing are necessary to determine the underlying cause of her symptoms.","Here are the findings and risk factors supporting each possible diagnosis:

**1. Acute Myocardial Infarction (AMI)**

* **Symptoms**: Crushing chest pain radiating to the left arm, which is a classic symptom of AMI.
* **Elevated Troponin I levels**: Troponin I is a cardiac biomarker that is elevated in the blood when there is damage to the heart muscle, as seen in AMI.
* **ST-segment elevation in leads V2-V4 on ECG**: This is a characteristic ECG finding of AMI, indicating damage to the heart muscle.
* **Risk factors**: The patient has a 10-year history of hypertension, which is a significant risk factor for coronary artery disease and AMI.
* **Family history**: Although the patient denies a family history of cardiac conditions or sudden death, her son's argument may have triggered a stress response that contributed to the AMI.

**2. Angina Pectoris**

* **Previous episodes of chest tightness**: The patient has had intermittent episodes of chest tightness in the past, which is a common symptom of angina pectoris.
* **Risk factors**: The patient has a 10-year history of hypertension, which is a risk factor for coronary artery disease and angina pectoris.
* **Lack of ST-segment elevation in all leads**: This finding is more consistent with angina pectoris, which typically does not cause ST-segment elevation on the ECG.
* **Absence of other symptoms**: The patient does not have nausea, vomiting, or syncope, which are more common in AMI.

**3. Cardiac Stress-Induced Condition**

* **Triggering event**: The patient's symptoms started after a heated argument, which suggests a possible stress-induced condition.
* **Elevated BNP levels**: BNP is a hormone that is released by the heart in response to stress and strain, and elevated levels are seen in conditions such as heart failure and stress-induced cardiomyopathy.
* **Mildly anxious and diaphoretic state**: The patient's physical examination findings suggest a stress response, which is consistent with a cardiac stress-induced condition.
* **Risk factors**: The patient's history of hypertension and osteoarthritis may contribute to a stress-induced condition, as these conditions can cause physical and emotional stress.

It is essential to note that these findings and risk factors are not exhaustive, and further evaluation and testing are necessary to determine the underlying cause of the patient's symptoms.","Here are the findings opposing each possible diagnosis:

**1. Acute Myocardial Infarction (AMI)**

* **Expected but not present findings**:
 + **Nausea and vomiting**: These symptoms are common in AMI, but the patient denies them.
 + **Syncope**: The patient does not report any episodes of fainting, which is unusual for AMI.
 + **Significant hypotension**: The patient's blood pressure is elevated (145/90 mmHg), which is not typical for AMI.
* **Findings opposing this hypothesis**:
 + **Lack of ST-segment elevation in all leads**: While the patient has ST-segment elevation in leads V2-V4, it is not present in all leads, which is unusual for AMI.
 + **Normal cardiac examination**: The patient's cardiac examination is normal, with no murmurs or gallops, which is not typical for AMI.

**2. Angina Pectoris**

* **Expected but not present findings**:
 + **Typical angina symptoms**: The patient's symptoms are more severe and crushing than typical angina, which is usually described as a squeezing or pressure sensation in the chest.
 + **Exertional symptoms**: The patient's symptoms started after a heated argument, which is not a typical trigger for angina.
 + **Significant ST-segment depression**: While the patient has ST-segment elevation in leads V2-V4, it is not typical for angina, which usually causes ST-segment depression.
* **Findings opposing this hypothesis**:
 + **Elevated troponin I levels**: The patient's troponin I levels are elevated, which is not typical for angina.
 + **ST-segment elevation in leads V2-V4**: This finding is more consistent with AMI than angina.

**3. Cardiac Stress-Induced Condition**

* **Expected but not present findings**:
 + **Significant ECG changes**: While the patient has some ECG changes, they are not as significant as would be expected for a cardiac stress-induced condition.
 + **More pronounced symptoms**: The patient's symptoms are more severe and crushing than would be expected for a cardiac stress-induced condition.
 + **More significant laboratory abnormalities**: The patient's laboratory abnormalities, such as elevated troponin I levels, are more consistent with AMI than a cardiac stress-induced condition.
* **Findings opposing this hypothesis**:
 + **Elevated troponin I levels**: The patient's troponin I levels are elevated, which is not typical for a cardiac stress-induced condition.
 + **ST-segment elevation in leads V2-V4**: This finding is more consistent with AMI than a cardiac stress-induced condition.","Based on the patient's symptoms, physical examination findings, laboratory results, and the analysis of the possible diagnoses, I would make the following final diagnosis:

**Acute Myocardial Infarction (AMI)**

The patient's symptoms of crushing chest pain radiating to the left arm, elevated troponin I levels (3.5 ng/mL), and ST-segment elevation in leads V2-V4 on the ECG are consistent with an AMI. The patient's history of hypertension and the lack of other symptoms such as nausea, vomiting, or syncope also support this diagnosis. While the patient's symptoms started after a heated argument, which could suggest a cardiac stress-induced condition, the presence of ST-segment elevation and elevated troponin I levels are more consistent with an AMI.

**Reasoning:**

* The patient's symptoms are consistent with an AMI, including crushing chest pain and ST-segment elevation on the ECG.
* The patient's laboratory results, including elevated troponin I levels, support this diagnosis.
* The patient's history of hypertension is a significant risk factor for coronary artery disease and AMI.
* The lack of other symptoms such as nausea, vomiting, or syncope makes a cardiac stress-induced condition less likely.
* The presence of ST-segment elevation in leads V2-V4 on the ECG is a characteristic finding of AMI.

**Treatment:**

* The patient should be treated with immediate medical therapy for AMI, including aspirin, beta-blockers, and statins.
* The patient should be evaluated for coronary artery disease and possible revascularization.
* The patient should be monitored closely for signs of complications, such as heart failure or arrhythmias.

**Follow-up:**

* The patient should be followed up with a cardiology consultation to further evaluate the extent of the myocardial infarction and to discuss possible revascularization options.
* The patient should be educated on the importance of lifestyle modifications, including smoking cessation, a healthy diet, and regular exercise, to reduce the risk of future cardiovascular events.","Based on the final diagnosis of Acute Myocardial Infarction (AMI), the following additional steps should be taken:

**Immediate Steps:**

1. **Activate the Cardiac Catheterization Laboratory (Cath Lab)**: The patient should be immediately transferred to the Cath Lab for coronary angiography and possible percutaneous coronary intervention (PCI) to restore blood flow to the affected area of the heart.
2. **Administer Medications**:
	* Aspirin: 325 mg orally to prevent platelet aggregation.
	* Beta-blockers: such as metoprolol or atenolol to reduce heart rate and blood pressure.
	* Statins: such as atorvastatin or simvastatin to lower cholesterol levels.
	* Nitroglycerin: to relieve chest pain and reduce blood pressure.
3. **Monitor Vital Signs**: Closely monitor the patient's vital signs, including heart rate, blood pressure, oxygen saturation, and cardiac rhythm.

**Diagnostic Tests:**

1. **Electrocardiogram (ECG)**: Repeat the ECG to monitor for any changes in the ST-segment elevation or development of new arrhythmias.
2. **Cardiac Biomarkers**: Repeat troponin I and creatine kinase (CK) levels to monitor for any changes in cardiac damage.
3. **Echocardiogram**: Perform an echocardiogram to evaluate the patient's left ventricular function and identify any wall motion abnormalities.

**Therapeutic Interventions:**

1. **Percutaneous Coronary Intervention (PCI)**: Perform PCI to restore blood flow to the affected area of the heart.
2. **Coronary Artery Bypass Grafting (CABG)**: Consider CABG if PCI is not feasible or if the patient has multi-vessel disease.
3. **Intra-aortic Balloon Pump (IABP)**: Consider IABP if the patient has severe left ventricular dysfunction or cardiogenic shock.

**Monitoring and Follow-up:**

1. **Cardiac Monitoring**: Continuously monitor the patient's cardiac rhythm and vital signs.
2. **Follow-up ECGs**: Repeat ECGs at regular intervals to monitor for any changes in the ST-segment elevation or development of new arrhythmias.
3. **Follow-up Cardiac Biomarkers**: Repeat troponin I and CK levels at regular intervals to monitor for any changes in cardiac damage.
4. **Follow-up Echocardiogram**: Repeat echocardiogram at regular intervals to evaluate the patient's left ventricular function and identify any wall motion abnormalities.

**Patient Education:**

1. **Smoking Cessation**: Educate the patient on the importance of smoking cessation to reduce the risk of future cardiovascular events.
2. **Healthy Diet**: Educate the patient on the importance of a healthy diet to reduce the risk of future cardiovascular events.
3. **Regular Exercise**: Educate the patient on the importance of regular exercise to reduce the risk of future cardiovascular events.
4. **Medication Adherence**: Educate the patient on the importance of medication adherence to reduce the risk of future cardiovascular events.","{""Score"":1,""Rationale"":""The answer includes Acute Myocardial Infarction, which matches the rubric. The other two diagnoses (Angina Pectoris and Cardiac Stress‑Induced Condition) do not correspond to the rubric terms Unstable Angina and Takotsubo Cardiomyopathy, so no points are awarded for them.""}","{""Score"":2,""Rationale"":""The answer includes elevated troponin and ST‑segment elevation in V2‑V4, matching the Acute Myocardial Infarction criteria (2 points). It lacks the required features for Takotsubo Cardiomyopathy (e.g., apical ballooning, normal angiography) and does not mention elevated troponin for Unstable Angina, so no points for those sections.""}","{""Score"":0,""Rationale"":""The student's answer does not mention any of the three diagnoses (Takotsubo cardiomyopathy, acute MI, unstable angina) or the specific opposing findings listed in the rubric; therefore no points are awarded.""}","{""Score"":0,""Rationale"":""The answer identifies the condition as Acute Myocardial Infarction (AMI) rather than the specific diagnosis required by the rubric, Acute Coronary Syndrome (Anterior STEMI). Although related, AMI is not the exact term or synonym specified, so no points are awarded.""}","{""Score"":2,""Rationale"":""The answer includes a follow-up echocardiogram, matching rubric item 2. It does not mention ACE inhibitors, psychological support, or referral to a cardiologist, so the other rubric items are not satisfied.""}",5.0
"History of Present Illness
A 65-year-old male with a history of type 2 diabetes and hypertension presents with a 2-hour history of crushing chest pain radiating to his left arm. He describes the pain as severe and constant, beginning after he climbed a flight of stairs. He is also feeling nauseated and sweaty. He is unable to recall a prior history of similar symptoms. He denies shortness of breath or palpitations but admits to feeling unusually fatigued for the last week.

  Past Medical History
Type 2 diabetes mellitus for 15 years, hypertension for 12 years, and hyperlipidemia. He is on metformin and a statin. He has no history of coronary artery disease or previous myocardial infarctions. He is a smoker (30 pack-years) and drinks alcohol occasionally. Family history is significant for cardiovascular disease, with both parents having had myocardial infarctions in their 50s

  Physical Examination
VITALS: BP 160/90 mmHg, pulse 110 bpm, temperature 98.5°F. 
GEN: Anxious and diaphoretic, in moderate distress due to chest pain. 
CARDIAC: Tachycardic, regular rhythm
PULM: Clear to auscultation bilaterally. 
ABD: Soft, non-tender, no hepatosplenomegaly. 
MSK: No tenderness or joint swelling. 
EXT: No edema. 
SKIN: Diaphoretic, cool extremities.

  Laboratory Results
Troponin I: 3.2 ng/mL (elevated). CBC: Normal. Serum glucose: 180 mg/dL (elevated).",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the provided history and physical examination, here are three possible diagnoses for the 65-year-old male patient:

1. **Acute Myocardial Infarction (AMI)**: The patient's symptoms of crushing chest pain radiating to the left arm, nausea, sweating, and elevated troponin I levels (3.2 ng/mL) are consistent with an AMI. The patient's history of type 2 diabetes, hypertension, and hyperlipidemia also increases his risk for coronary artery disease.

2. **Unstable Angina**: Although the patient's symptoms are similar to those of an AMI, the lack of a clear history of previous coronary artery disease or previous myocardial infarctions, and the absence of shortness of breath or palpitations, make unstable angina a possible diagnosis. Unstable angina is characterized by chest pain that is new or worsening, and is often associated with an elevated troponin level.

3. **Pulmonary Embolism (PE)**: Although the patient's physical examination is clear to auscultation bilaterally, and there is no mention of a recent history of travel or surgery, a PE cannot be ruled out. The patient's symptoms of chest pain, nausea, and sweating, combined with his history of smoking and family history of cardiovascular disease, make a PE a possible diagnosis. However, further testing such as a CT pulmonary angiogram would be needed to confirm this diagnosis.

It is essential to note that these diagnoses are not mutually exclusive, and further testing and evaluation may be necessary to determine the correct diagnosis.","Here are the findings and risk factors supporting each possible diagnosis:

**Acute Myocardial Infarction (AMI)**

1. **Symptoms**: The patient's symptoms of crushing chest pain radiating to the left arm, nausea, sweating, and fatigue are classic for an AMI.
2. **Elevated Troponin I**: The patient's troponin I level is significantly elevated at 3.2 ng/mL, which is a strong indicator of myocardial damage.
3. **Risk Factors**: The patient has a history of type 2 diabetes, hypertension, and hyperlipidemia, which are all significant risk factors for coronary artery disease.
4. **Family History**: The patient's family history of cardiovascular disease, with both parents having had myocardial infarctions in their 50s, further increases his risk.
5. **Physical Examination**: The patient's tachycardia, diaphoresis, and anxiety are all consistent with an AMI.

**Unstable Angina**

1. **Symptoms**: The patient's symptoms of chest pain radiating to the left arm, nausea, and sweating are similar to those of an AMI, but the pain is not necessarily new or worsening.
2. **Elevated Troponin I**: The patient's troponin I level is elevated, which is a common finding in unstable angina.
3. **Risk Factors**: The patient's history of type 2 diabetes, hypertension, and hyperlipidemia increases his risk for coronary artery disease.
4. **Physical Examination**: The patient's tachycardia, diaphoresis, and anxiety are all consistent with unstable angina.

**Pulmonary Embolism (PE)**

1. **Symptoms**: The patient's symptoms of chest pain, nausea, and sweating are similar to those of an AMI or unstable angina, but the pain is often described as pleuritic (sharp and stabbing).
2. **Risk Factors**: The patient's history of smoking and family history of cardiovascular disease increases his risk for a PE.
3. **Physical Examination**: The patient's tachycardia and diaphoresis are consistent with a PE.
4. **Laboratory Results**: The patient's normal CBC and serum glucose levels do not rule out a PE, but further testing such as a CT pulmonary angiogram would be needed to confirm this diagnosis.

It is essential to note that these findings and risk factors are not exhaustive, and further testing and evaluation may be necessary to determine the correct diagnosis.","Here are the findings opposing each possible diagnosis:

**Acute Myocardial Infarction (AMI)**

1. **Expected but not present**: The patient's shortness of breath or palpitations are not mentioned, which is unusual for an AMI. Typically, patients with AMI experience some degree of respiratory distress or arrhythmias.
2. **Lack of previous MI or CAD**: The patient has no history of previous myocardial infarctions or coronary artery disease, which makes an AMI less likely.
3. **Normal ECG**: Although not mentioned, a normal ECG would be expected in the absence of an AMI. The patient's ECG is not mentioned, but if it were normal, it would oppose the diagnosis of AMI.
4. **No mention of ST-elevation**: ST-elevation is a hallmark of AMI, and its absence would oppose this diagnosis.

**Unstable Angina**

1. **Expected but not present**: The patient's symptoms are not new or worsening, which is a key characteristic of unstable angina. Typically, patients with unstable angina experience a change in their usual pattern of chest pain.
2. **Lack of risk factors for CAD progression**: The patient's risk factors for coronary artery disease progression, such as a history of previous MI or CAD, are not mentioned.
3. **Normal ECG**: Although not mentioned, a normal ECG would be expected in the absence of unstable angina. The patient's ECG is not mentioned, but if it were normal, it would oppose the diagnosis of unstable angina.
4. **No mention of recent change in symptoms**: The patient's symptoms have not changed recently, which is a key characteristic of unstable angina.

**Pulmonary Embolism (PE)**

1. **Expected but not present**: The patient's shortness of breath is not mentioned, which is a common symptom of PE. Typically, patients with PE experience some degree of respiratory distress.
2. **Lack of risk factors for PE**: The patient's risk factors for PE, such as recent surgery, trauma, or immobility, are not mentioned.
3. **Normal D-dimer**: Although not mentioned, a normal D-dimer would be expected in the absence of PE. The patient's D-dimer is not mentioned, but if it were normal, it would oppose the diagnosis of PE.
4. **No mention of recent travel or surgery**: The patient's recent travel or surgery history is not mentioned, which would be expected in the absence of PE.

It is essential to note that these findings opposing each possible diagnosis are not exhaustive, and further testing and evaluation may be necessary to determine the correct diagnosis.","Based on the provided history, physical examination, and laboratory results, I would make the following final diagnosis:

**Acute Myocardial Infarction (AMI)**

The patient's symptoms of crushing chest pain radiating to the left arm, nausea, sweating, and fatigue, combined with his elevated troponin I level (3.2 ng/mL), strongly suggest an AMI. The patient's history of type 2 diabetes, hypertension, and hyperlipidemia, as well as his family history of cardiovascular disease, further increase his risk for coronary artery disease.

While unstable angina and pulmonary embolism are possible diagnoses, the patient's symptoms and laboratory results are more consistent with an AMI. The patient's tachycardia, diaphoresis, and anxiety are all consistent with an AMI, and the elevated troponin I level is a strong indicator of myocardial damage.

**Treatment Plan**

Based on the diagnosis of AMI, the following treatment plan would be implemented:

1. **Oxygen therapy**: The patient would be started on oxygen therapy to maintain an oxygen saturation of 92% or higher.
2. **Aspirin**: The patient would be given aspirin 325 mg orally to prevent further clot formation.
3. **Nitroglycerin**: The patient would be given nitroglycerin 0.4 mg sublingually to relieve chest pain.
4. **Beta-blockers**: The patient would be started on beta-blockers to reduce myocardial oxygen demand and prevent further ischemia.
5. **Angiotensin-converting enzyme (ACE) inhibitors**: The patient would be started on ACE inhibitors to reduce blood pressure and prevent further cardiac damage.
6. **Pain management**: The patient would be given pain medication, such as morphine, to manage chest pain.
7. **Cardiac catheterization**: The patient would undergo cardiac catheterization to assess the extent of coronary artery disease and to perform any necessary interventions, such as angioplasty or stenting.

**Monitoring**

The patient would be closely monitored for any signs of complications, such as cardiac arrest, arrhythmias, or cardiac failure. The patient's vital signs, including blood pressure, heart rate, and oxygen saturation, would be closely monitored, and any changes would be promptly addressed.","Based on the diagnosis of Acute Myocardial Infarction (AMI), the following additional steps would be taken:

**Immediate Steps**

1. **Activate the cardiac catheterization lab**: The patient would be immediately transferred to the cardiac catheterization lab for emergency angiography and possible intervention.
2. **Administer thrombolytic therapy**: If the patient is eligible, thrombolytic therapy would be administered to dissolve the clot causing the AMI.
3. **Monitor for complications**: The patient would be closely monitored for any signs of complications, such as cardiac arrest, arrhythmias, or cardiac failure.

**Laboratory Tests**

1. **Complete Blood Count (CBC)**: A CBC would be repeated to monitor for any changes in the patient's white blood cell count or platelet count.
2. **Electrolyte panel**: An electrolyte panel would be repeated to monitor for any changes in the patient's potassium, magnesium, or calcium levels.
3. **Troponin I**: Troponin I levels would be repeated to monitor for any changes in the patient's cardiac damage.
4. **Creatine kinase (CK)**: CK levels would be repeated to monitor for any changes in the patient's cardiac damage.

**Imaging Studies**

1. **Electrocardiogram (ECG)**: A 12-lead ECG would be repeated to monitor for any changes in the patient's cardiac rhythm or ischemia.
2. **Echocardiogram**: An echocardiogram would be performed to assess the patient's cardiac function and to monitor for any signs of cardiac failure.
3. **Cardiac computed tomography (CT) scan**: A cardiac CT scan would be performed to assess the patient's coronary artery disease and to monitor for any signs of cardiac damage.

**Medications**

1. **Aspirin**: Aspirin would be continued to prevent further clot formation.
2. **Beta-blockers**: Beta-blockers would be continued to reduce myocardial oxygen demand and prevent further ischemia.
3. **ACE inhibitors**: ACE inhibitors would be continued to reduce blood pressure and prevent further cardiac damage.
4. **Pain management**: Pain medication, such as morphine, would be continued to manage chest pain.

**Cardiac Rehabilitation**

1. **Cardiac rehabilitation program**: The patient would be referred to a cardiac rehabilitation program to participate in exercise and education to improve cardiac function and to reduce the risk of future cardiac events.

**Follow-up**

1. **Follow-up appointment**: The patient would be scheduled for a follow-up appointment with the cardiologist to monitor for any changes in the patient's cardiac function and to assess the patient's response to treatment.
2. **Cardiac catheterization**: The patient would undergo cardiac catheterization at a later date to assess the extent of coronary artery disease and to perform any necessary interventions, such as angioplasty or stenting.","{""Score"":2,""Rationale"":""The answer includes Acute Myocardial Infarction (AMI) and Unstable Angina, which match two of the three rubric items. It does not include Gastroesophageal Reflux Disease (GERD) and adds an unrelated diagnosis (Pulmonary Embolism), so only 2 points are awarded.""}","{""Score"":0,""Rationale"":""The answer omits the ST‑segment elevation in leads II, III, aVF required for the MI description, misstates troponin elevation as typical for unstable angina, and does not address GERD; therefore none of the rubric concepts are fully matched.""}","{""Score"":0,""Rationale"":""The answer does not provide the opposing findings specified in the rubric for Acute MI, Unstable Angina, or GERD, and introduces an unrelated diagnosis (PE).""}","{""Score"":2,""Rationale"":""The answer correctly identifies Acute Myocardial Infarction (AMI) and provides matching clinical features (crushing chest pain, elevated troponin, risk factors) as described in the high‑scoring example, thus earning full credit.""}","{""Score"":2,""Rationale"":""The answer includes cardiac catheterization/angiography, matching the third rubric item, but does not mention both aspirin and heparin together nor nitroglycerin, so only 2 of the 6 possible points are earned.""}",6.0
"History of Present Illness
A 60-year-old male with a recent history of hip replacement surgery 2 weeks ago presents with sudden onset of shortness of breath and pleuritic chest pain. The pain is sharp and worsens with deep breathing or coughing. He has been feeling progressively more breathless, even while at rest, and also reports a mild cough. He denies fever or hemoptysis but admits to feeling fatigued and dizzy on exertion. He has not been able to move around much post-surgery, and has been primarily confined to bed. He has no known history of deep vein thrombosis (DVT).

  Past Medical History
He has a history of osteoarthritis, for which he underwent the recent hip replacement. He has no known history of cardiovascular or respiratory disease. No significant family history of pulmonary embolism or clotting disorders. He is a non-smoker and does not drink alcohol.

  Physical Examination
VITALS: BP 130/85 mmHg, pulse 110 bpm, temperature 98.7°F, respiratory rate 22/min. GEN: Mildly anxious, appears in moderate distress due to breathing difficulties. CARDIAC: Tachycardic, regular rhythm, no murmurs. 
PULM: Tachypneic, decreased breath sounds at the right base, no wheezing. 
ABD: Soft, non-tender. 
MSK: Limited movement of the right hip due to recent surgery. 
EXT: Mild swelling in the right lower leg, no redness or warmth. 
SKIN: No rashes, warm extremities.

  Laboratory Results
D-dimer: 8.5 µg/mL (elevated). Chest CT angiogram: Acute pulmonary embolism in the right lower lobe pulmonary artery. ABG: pO2 70 mmHg, pCO2 35 mmHg.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's history and physical examination, the following are three possible diagnoses:

1. **Pulmonary Embolism (PE)**: The patient's sudden onset of shortness of breath, pleuritic chest pain, and elevated D-dimer levels are consistent with a pulmonary embolism. The chest CT angiogram confirms the diagnosis, showing an acute pulmonary embolism in the right lower lobe pulmonary artery.

2. **Deep Vein Thrombosis (DVT) with Pulmonary Embolism**: Although the patient denies a history of DVT, the mild swelling in the right lower leg and elevated D-dimer levels suggest the possibility of a DVT, which could have led to the pulmonary embolism.

3. **Acute Respiratory Distress Syndrome (ARDS)**: The patient's tachypnea, decreased breath sounds at the right base, and low pO2 levels on the ABG could be indicative of ARDS, which is a life-threatening condition that requires immediate medical attention. However, the presence of a pulmonary embolism on the chest CT angiogram makes this diagnosis less likely.

It's worth noting that the patient's recent hip replacement surgery and prolonged bed rest increase the risk of developing a pulmonary embolism, making this diagnosis the most likely.","Here are the findings and risk factors supporting each possible diagnosis:

**Pulmonary Embolism (PE)**

1. **Recent hip replacement surgery**: The patient underwent a recent hip replacement surgery, which increases the risk of developing a pulmonary embolism due to prolonged bed rest and immobility.
2. **Prolonged bed rest**: The patient has been confined to bed for an extended period, which increases the risk of developing a DVT and subsequent PE.
3. **Elevated D-dimer levels**: The patient's D-dimer level is elevated, which is a sensitive but non-specific marker for thrombosis.
4. **Chest CT angiogram findings**: The chest CT angiogram confirms the diagnosis of a pulmonary embolism in the right lower lobe pulmonary artery.
5. **Symptoms of PE**: The patient's sudden onset of shortness of breath, pleuritic chest pain, and tachypnea are consistent with a pulmonary embolism.

**Deep Vein Thrombosis (DVT) with Pulmonary Embolism**

1. **Mild swelling in the right lower leg**: The patient has mild swelling in the right lower leg, which could be indicative of a DVT.
2. **Elevated D-dimer levels**: The patient's D-dimer level is elevated, which is a sensitive but non-specific marker for thrombosis.
3. **Recent hip replacement surgery**: The patient underwent a recent hip replacement surgery, which increases the risk of developing a DVT and subsequent PE.
4. **Prolonged bed rest**: The patient has been confined to bed for an extended period, which increases the risk of developing a DVT.
5. **Symptoms of DVT**: The patient's mild swelling in the right lower leg and lack of redness or warmth suggest a possible DVT.

**Acute Respiratory Distress Syndrome (ARDS)**

1. **Tachypnea**: The patient is tachypneic, which is a common finding in ARDS.
2. **Decreased breath sounds at the right base**: The patient has decreased breath sounds at the right base, which could be indicative of ARDS.
3. **Low pO2 levels**: The patient's pO2 level is low, which is consistent with ARDS.
4. **Recent hip replacement surgery**: The patient underwent a recent hip replacement surgery, which increases the risk of developing ARDS due to prolonged bed rest and immobility.
5. **Prolonged bed rest**: The patient has been confined to bed for an extended period, which increases the risk of developing ARDS.

However, the presence of a pulmonary embolism on the chest CT angiogram makes ARDS less likely.","Here are the findings opposing each possible diagnosis:

**Pulmonary Embolism (PE)**

1. **Expected but not present: Fever**: Fever is a common finding in pulmonary embolism, but the patient denies fever.
2. **Expected but not present: Hemoptysis**: Hemoptysis is a common finding in pulmonary embolism, but the patient denies hemoptysis.
3. **Expected but not present: Tachycardia out of proportion to respiratory rate**: While the patient is tachycardic, the tachycardia is not out of proportion to the respiratory rate, which is a common finding in pulmonary embolism.
4. **Expected but not present: Elevated blood pressure**: Elevated blood pressure is a common finding in pulmonary embolism, but the patient's blood pressure is within normal limits.
5. **Not expected: Mild swelling in the right lower leg**: While the patient has mild swelling in the right lower leg, this is not a typical finding in pulmonary embolism. DVT is a more likely explanation for this finding.

**Deep Vein Thrombosis (DVT) with Pulmonary Embolism**

1. **Expected but not present: Redness or warmth in the affected limb**: Redness or warmth in the affected limb is a common finding in DVT, but the patient does not have these symptoms.
2. **Expected but not present: Pain in the affected limb**: Pain in the affected limb is a common finding in DVT, but the patient does not report pain in the right lower leg.
3. **Expected but not present: Swelling in the affected limb**: While the patient has mild swelling in the right lower leg, this is not a typical finding in DVT. The swelling is mild and not accompanied by redness or warmth.
4. **Not expected: Tachypnea**: While the patient is tachypneic, this is not a typical finding in DVT. Tachypnea is more commonly associated with pulmonary embolism.
5. **Not expected: Elevated D-dimer levels**: While the patient's D-dimer level is elevated, this is not a specific finding for DVT. Elevated D-dimer levels can be seen in a variety of conditions, including pulmonary embolism.

**Acute Respiratory Distress Syndrome (ARDS)**

1. **Expected but not present: Bilateral infiltrates on chest radiograph**: Bilateral infiltrates on chest radiograph are a common finding in ARDS, but the patient's chest CT angiogram shows a unilateral pulmonary embolism.
2. **Expected but not present: Hypotension**: Hypotension is a common finding in ARDS, but the patient's blood pressure is within normal limits.
3. **Expected but not present: Elevated lactate levels**: Elevated lactate levels are a common finding in ARDS, but the patient's lactate level is not mentioned.
4. **Not expected: Pulmonary embolism on chest CT angiogram**: The presence of a pulmonary embolism on the chest CT angiogram makes ARDS less likely.
5. **Not expected: Mild swelling in the right lower leg**: While the patient has mild swelling in the right lower leg, this is not a typical finding in ARDS. The swelling is more likely related to DVT or pulmonary embolism.","Based on the patient's history, physical examination, laboratory results, and the findings supporting and opposing each possible diagnosis, the final diagnosis is:

**Pulmonary Embolism (PE)**

The patient's recent hip replacement surgery, prolonged bed rest, and elevated D-dimer levels increase the risk of developing a pulmonary embolism. The chest CT angiogram confirms the diagnosis, showing an acute pulmonary embolism in the right lower lobe pulmonary artery. The patient's symptoms of shortness of breath, pleuritic chest pain, and tachypnea are consistent with a pulmonary embolism.

While the patient has mild swelling in the right lower leg, this is more likely related to DVT or pulmonary embolism rather than ARDS. The patient's lack of fever, hemoptysis, and hypotension also make ARDS less likely.

The final diagnosis is:

**Pulmonary Embolism (PE)**

**Treatment Plan:**

1. **Anticoagulation therapy**: The patient will be started on anticoagulation therapy to prevent further clot formation and to allow the existing clot to dissolve.
2. **Oxygen therapy**: The patient will be started on oxygen therapy to help improve oxygenation and reduce symptoms.
3. **Pain management**: The patient will be managed with pain medication to help alleviate symptoms of pleuritic chest pain.
4. **Monitoring**: The patient will be closely monitored for signs of complications, such as respiratory failure or cardiac arrest.
5. **Follow-up**: The patient will be followed up with regular check-ups to monitor the resolution of the pulmonary embolism and to adjust treatment as needed.

**Prognosis:**

The prognosis for patients with pulmonary embolism is generally good, especially if treated promptly and effectively. However, the patient's underlying medical condition and the severity of the pulmonary embolism can affect the prognosis. In this case, the patient's recent hip replacement surgery and prolonged bed rest increase the risk of complications.","Based on the patient's diagnosis of pulmonary embolism, the following additional steps should be taken:

**Immediate Steps:**

1. **Activate the hospital's pulmonary embolism protocol**: This will ensure that the patient receives timely and effective treatment.
2. **Administer anticoagulation therapy**: The patient should be started on anticoagulation therapy, such as heparin or low molecular weight heparin, to prevent further clot formation and to allow the existing clot to dissolve.
3. **Monitor the patient's vital signs**: The patient's vital signs, including oxygen saturation, heart rate, and blood pressure, should be closely monitored.
4. **Perform a repeat D-dimer test**: A repeat D-dimer test should be performed to confirm the resolution of the pulmonary embolism.

**Short-term Steps:**

1. **Order a repeat chest CT angiogram**: A repeat chest CT angiogram should be ordered to confirm the resolution of the pulmonary embolism.
2. **Monitor for signs of complications**: The patient should be closely monitored for signs of complications, such as respiratory failure or cardiac arrest.
3. **Adjust anticoagulation therapy**: The patient's anticoagulation therapy should be adjusted as needed to prevent further clot formation.
4. **Provide pain management**: The patient should be managed with pain medication to help alleviate symptoms of pleuritic chest pain.

**Long-term Steps:**

1. **Order a follow-up chest CT angiogram**: A follow-up chest CT angiogram should be ordered to confirm the resolution of the pulmonary embolism.
2. **Monitor for signs of post-thrombotic syndrome**: The patient should be closely monitored for signs of post-thrombotic syndrome, such as chronic pain, swelling, and skin changes.
3. **Provide education on anticoagulation therapy**: The patient should be educated on the importance of anticoagulation therapy and how to manage it.
4. **Schedule follow-up appointments**: The patient should be scheduled for follow-up appointments to monitor the resolution of the pulmonary embolism and to adjust treatment as needed.

**Prevention of Future Pulmonary Embolism:**

1. **Order a thrombophilia workup**: A thrombophilia workup should be ordered to identify any underlying conditions that may have contributed to the pulmonary embolism.
2. **Recommend compression stockings**: The patient should be recommended to wear compression stockings to help prevent future pulmonary embolism.
3. **Recommend regular exercise**: The patient should be recommended to engage in regular exercise to help prevent future pulmonary embolism.
4. **Recommend smoking cessation**: The patient should be recommended to quit smoking to help prevent future pulmonary embolism.

**Discharge Planning:**

1. **Develop a discharge plan**: A discharge plan should be developed to ensure that the patient receives the necessary care and support after discharge.
2. **Provide education on anticoagulation therapy**: The patient should be educated on the importance of anticoagulation therapy and how to manage it.
3. **Recommend follow-up appointments**: The patient should be recommended to schedule follow-up appointments to monitor the resolution of the pulmonary embolism and to adjust treatment as needed.
4. **Provide resources for support**: The patient should be provided with resources for support, such as a pulmonary embolism support group.","{""Score"":2,""Rationale"":""The answer includes Pulmonary Embolism and Deep Vein Thrombosis, which match two items in the rubric, but does not include Pneumonia; thus 2 of 3 points are earned.""}","{""Score"":4,""Rationale"":""The answer includes the required risk factors and findings for Pulmonary Embolism and Deep Vein Thrombosis as listed in the high‑scoring example, earning 2 points each. It does not address Pneumonia at all, so no points are awarded for that component. Total points = 4 out of 6.""}","{""Score"":0,""Rationale"":""Student answer does not match any of the required opposing findings for PE, Pneumonia, or DVT as listed in the rubric; it omits Pneumonia entirely and provides unrelated or contradictory points for PE and DVT.""}","{""Score"":2,""Rationale"":""The answer correctly identifies Pulmonary Embolism (PE) and includes the key elements from the rubric: sudden shortness of breath, pleuritic chest pain, elevated D-dimer, and confirmation on CT angiogram, thus meeting the high‑scoring example.""}","{""Score"":2,""Rationale"":""The answer includes anticoagulation therapy, matching one rubric item (2 points). It does not mention oxygen therapy or ultrasound evaluation for DVT, so no points for those items.""}",10.0
"History of Present Illness
A 74-year-old female presents with a 1-month history of progressive fatigue, dizziness, and pale appearance. Over the last two weeks, she has noticed intermittent black, tarry stools and occasional bright red blood after bowel movements. She denies significant abdominal pain, nausea, or vomiting but mentions a history of occasional heartburn, which she manages with over-the-counter antacids. She has no history of hemorrhoids or significant gastrointestinal issues. She does not recall recent weight loss, but reports feeling more fatigued than usual.

  Past Medical History
She has a history of hypertension, controlled with an angiotensin II receptor blocker, and osteoarthritis. She is a former smoker (quit 10 years ago) and consumes alcohol occasionally. No family history of gastrointestinal cancers or bleeding disorders.

  Physical Examination
VITALS: BP 110/70 mmHg, pulse 88 bpm, temperature 98.2°F. 
GEN: Pale and fatigued-appearing. 
CARDIAC: Regular rhythm, no murmurs. 
PULM: Clear to auscultation bilaterally. 
ABD: Mild epigastric tenderness, no hepatosplenomegaly. No rebound tenderness or guarding. 
EXT: No edema, peripheral pulses intact. 
SKIN: Pale conjunctiva, no jaundice.

  Laboratory Results
Hemoglobin: 8.9 g/dL (low). Hematocrit: 27% (low). Platelets: 150 x 10^3/μL. Fecal occult blood test: Positive. Colonoscopy: Findings of multiple diverticula with no active bleeding. No masses or polyps observed.",List 3 Possible Diagnoses,"Support Diagnosis 

For each possible diagnosis, provide findings/risk factors supporting this hypothesis ","Opposing Diagnosis 

For each possible diagnosis, provide findings opposing this hypothesis, or findings that were expected but not present ",Final Diagnosis,Additional Steps ,"Based on the patient's symptoms and laboratory results, here are three possible diagnoses:

1. **Iron Deficiency Anemia (IDA)**: The patient's low hemoglobin and hematocrit levels, along with the presence of black, tarry stools (melena) and occasional bright red blood after bowel movements, suggest chronic blood loss leading to iron deficiency anemia. The colonoscopy findings of multiple diverticula with no active bleeding support this diagnosis, as diverticula can cause chronic blood loss.

2. **Gastroesophageal Reflux Disease (GERD) with Esophageal or Gastric Ulcer**: The patient's history of heartburn and occasional bright red blood after bowel movements could be related to GERD, which can cause esophageal or gastric ulcers. However, the colonoscopy findings do not support this diagnosis, and the patient's symptoms do not strongly suggest an ulcer.

3. **Diverticular Bleeding**: The patient's colonoscopy findings of multiple diverticula with no active bleeding, along with the presence of black, tarry stools and occasional bright red blood after bowel movements, suggest diverticular bleeding. This is a common cause of lower gastrointestinal bleeding in older adults.

It's worth noting that the patient's low hemoglobin and hematocrit levels suggest chronic blood loss, which is more consistent with iron deficiency anemia or diverticular bleeding than with acute gastrointestinal bleeding.","Here are the findings and risk factors supporting each possible diagnosis:

**Iron Deficiency Anemia (IDA)**

1. **Low hemoglobin and hematocrit levels**: The patient's hemoglobin level of 8.9 g/dL and hematocrit level of 27% are significantly below the normal range, indicating iron deficiency anemia.
2. **Black, tarry stools (melena)**: Melena is a common symptom of chronic gastrointestinal bleeding, which can lead to iron deficiency anemia.
3. **Occasional bright red blood after bowel movements**: This symptom suggests intermittent bleeding, which can contribute to iron deficiency anemia.
4. **Colonoscopy findings of multiple diverticula**: Diverticula can cause chronic blood loss, leading to iron deficiency anemia.
5. **History of heartburn**: Although not directly related to iron deficiency anemia, heartburn can be a symptom of gastroesophageal reflux disease (GERD), which can increase the risk of bleeding from diverticula.

**Gastroesophageal Reflux Disease (GERD) with Esophageal or Gastric Ulcer**

1. **History of heartburn**: The patient's history of heartburn suggests GERD, which can increase the risk of esophageal or gastric ulcers.
2. **Occasional bright red blood after bowel movements**: This symptom can be associated with ulcers, although it is more commonly associated with diverticular bleeding.
3. **Mild epigastric tenderness**: This finding can be associated with ulcers or GERD.

However, the following findings do not strongly support this diagnosis:

* Colonoscopy findings of multiple diverticula with no active bleeding
* No family history of gastrointestinal cancers or bleeding disorders

**Diverticular Bleeding**

1. **Colonoscopy findings of multiple diverticula**: Diverticula are a common cause of lower gastrointestinal bleeding in older adults.
2. **Black, tarry stools (melena)**: Melena is a common symptom of diverticular bleeding.
3. **Occasional bright red blood after bowel movements**: This symptom can be associated with diverticular bleeding.
4. **History of heartburn**: Although not directly related to diverticular bleeding, heartburn can be a symptom of GERD, which can increase the risk of bleeding from diverticula.

However, the following findings do not strongly support this diagnosis:

* Low hemoglobin and hematocrit levels, which suggest chronic blood loss rather than acute bleeding
* No family history of gastrointestinal cancers or bleeding disorders","Here are the findings opposing each possible diagnosis:

**Iron Deficiency Anemia (IDA)**

1. **Expected but not present: Active bleeding on colonoscopy**: If the patient had active bleeding, it would be expected to be visible on colonoscopy. The absence of active bleeding suggests that the bleeding may be intermittent or related to diverticula.
2. **Expected but not present: Significant abdominal pain**: Patients with iron deficiency anemia often experience significant abdominal pain, which was not reported by the patient.
3. **Expected but not present: Weight loss**: Patients with iron deficiency anemia often experience weight loss, which was not reported by the patient.
4. **Not expected: Normal platelet count**: A normal platelet count suggests that the bleeding is not related to a platelet disorder, which is consistent with diverticular bleeding.

**Gastroesophageal Reflux Disease (GERD) with Esophageal or Gastric Ulcer**

1. **Expected but not present: Esophageal or gastric ulcers on endoscopy**: If the patient had an esophageal or gastric ulcer, it would be expected to be visible on endoscopy. The absence of ulcers suggests that the bleeding may be related to diverticula.
2. **Expected but not present: Significant abdominal pain**: Patients with esophageal or gastric ulcers often experience significant abdominal pain, which was not reported by the patient.
3. **Expected but not present: History of bleeding disorders**: Patients with esophageal or gastric ulcers often have a history of bleeding disorders, which was not reported by the patient.
4. **Not expected: Normal platelet count**: A normal platelet count suggests that the bleeding is not related to a platelet disorder, which is consistent with diverticular bleeding.

**Diverticular Bleeding**

1. **Expected but not present: Active bleeding on colonoscopy**: If the patient had active bleeding, it would be expected to be visible on colonoscopy. The absence of active bleeding suggests that the bleeding may be intermittent or related to another cause.
2. **Expected but not present: Significant abdominal pain**: Patients with diverticular bleeding often experience significant abdominal pain, which was not reported by the patient.
3. **Expected but not present: Weight loss**: Patients with diverticular bleeding often experience weight loss, which was not reported by the patient.
4. **Not expected: Low hemoglobin and hematocrit levels**: A low hemoglobin and hematocrit levels suggest chronic blood loss, which is more consistent with iron deficiency anemia than with diverticular bleeding.

However, the following findings support diverticular bleeding:

* Colonoscopy findings of multiple diverticula
* Black, tarry stools (melena)
* Occasional bright red blood after bowel movements","Based on the patient's symptoms, laboratory results, and colonoscopy findings, the final diagnosis is:

**Iron Deficiency Anemia (IDA) due to Diverticular Bleeding**

The patient's low hemoglobin and hematocrit levels, along with the presence of black, tarry stools (melena) and occasional bright red blood after bowel movements, suggest chronic blood loss leading to iron deficiency anemia. The colonoscopy findings of multiple diverticula with no active bleeding support this diagnosis, as diverticula can cause chronic blood loss.

The patient's history of heartburn and occasional bright red blood after bowel movements could be related to gastroesophageal reflux disease (GERD), but the colonoscopy findings do not support this diagnosis. The patient's symptoms and laboratory results do not strongly suggest an esophageal or gastric ulcer.

Diverticular bleeding is a common cause of lower gastrointestinal bleeding in older adults, and the patient's symptoms and colonoscopy findings are consistent with this diagnosis. However, the patient's low hemoglobin and hematocrit levels suggest chronic blood loss, which is more consistent with iron deficiency anemia than with acute diverticular bleeding.

**Management Plan**

1. **Iron supplementation**: The patient will be started on iron supplements to correct the iron deficiency anemia.
2. **Colonoscopy follow-up**: The patient will be scheduled for a follow-up colonoscopy to evaluate the diverticula and rule out any other causes of bleeding.
3. **Endoscopy**: The patient may require an endoscopy to evaluate the esophagus and stomach for any signs of bleeding or ulcers.
4. **Lifestyle modifications**: The patient will be advised to make lifestyle modifications, such as increasing fiber intake and staying hydrated, to help manage the diverticula and prevent future bleeding episodes.

**Prognosis**

The patient's prognosis is good with proper management and treatment. Iron deficiency anemia can be effectively treated with iron supplements, and the patient's symptoms should improve with time. Diverticular bleeding is a common condition in older adults, and the patient's symptoms and colonoscopy findings are consistent with this diagnosis. With proper management and treatment, the patient's symptoms should improve, and the risk of future bleeding episodes should decrease.","Based on the patient's diagnosis of Iron Deficiency Anemia (IDA) due to Diverticular Bleeding, the following additional steps should be taken:

**Short-term management**

1. **Iron supplementation**: The patient will be started on iron supplements to correct the iron deficiency anemia. The type and dosage of iron supplement will depend on the patient's specific needs and medical history.
2. **Folic acid supplementation**: The patient will be started on folic acid supplements to help prevent anemia and support red blood cell production.
3. **Blood transfusion**: If the patient's hemoglobin level is critically low, a blood transfusion may be necessary to quickly increase the red blood cell count.
4. **Fluid and electrolyte management**: The patient will be monitored for signs of dehydration and electrolyte imbalances, and fluid and electrolyte replacement therapy will be administered as needed.

**Long-term management**

1. **Colonoscopy follow-up**: The patient will be scheduled for a follow-up colonoscopy to evaluate the diverticula and rule out any other causes of bleeding.
2. **Endoscopy**: The patient may require an endoscopy to evaluate the esophagus and stomach for any signs of bleeding or ulcers.
3. **Lifestyle modifications**: The patient will be advised to make lifestyle modifications, such as:
	* Increasing fiber intake to help manage the diverticula and prevent future bleeding episodes.
	* Staying hydrated to help prevent constipation and reduce the risk of bleeding.
	* Avoiding heavy lifting, bending, or straining, which can exacerbate the diverticula and increase the risk of bleeding.
	* Quitting smoking, if applicable, to reduce the risk of bleeding and other complications.
4. **Regular follow-up**: The patient will be scheduled for regular follow-up appointments to monitor their hemoglobin level, iron supplementation, and overall health.

**Prevention of future bleeding episodes**

1. **Diverticulitis prevention**: The patient will be advised to take steps to prevent diverticulitis, such as:
	* Eating a high-fiber diet to help manage the diverticula and prevent constipation.
	* Staying hydrated to help prevent constipation and reduce the risk of bleeding.
	* Avoiding heavy lifting, bending, or straining, which can exacerbate the diverticula and increase the risk of bleeding.
2. **Regular colonoscopy**: The patient will be scheduled for regular colonoscopies to evaluate the diverticula and rule out any other causes of bleeding.
3. **Endoscopy**: The patient may require regular endoscopies to evaluate the esophagus and stomach for any signs of bleeding or ulcers.

**Patient education**

1. **Iron deficiency anemia**: The patient will be educated on the causes, symptoms, and treatment of iron deficiency anemia.
2. **Diverticular bleeding**: The patient will be educated on the causes, symptoms, and treatment of diverticular bleeding.
3. **Lifestyle modifications**: The patient will be advised on the importance of making lifestyle modifications to help manage the diverticula and prevent future bleeding episodes.
4. **Regular follow-up**: The patient will be advised on the importance of regular follow-up appointments to monitor their hemoglobin level, iron supplementation, and overall health.","{""Score"":1,""Rationale"":""Student mentions a gastric ulcer (as part of GERD with Esophageal or Gastric Ulcer), which aligns with Peptic Ulcer Disease, but does not list Gastritis or Gastrointestinal Malignancy; thus only one of the three rubric items is present.""}","{""Score"":0,""Rationale"":""The answer does not mention any of the rubric's required diagnoses (Peptic Ulcer Disease, Gastritis with Chronic GI Bleeding, Gastrointestinal Malignancy) and therefore receives no points.""}","{""Score"":0,""Rationale"":""Student answer does not contain any of the rubric's required concepts (NSAID use, endoscopic confirmation, weight loss, mass, colonoscopy findings), thus no points are awarded.""}","{
  ""Score"": 0,
  ""Rationale"": ""The answer does not match the high scoring example; it lacks the positive fecal occult blood test and incorrectly attributes the findings to diverticular bleeding rather than supporting an upper GI source as required.""
}","{""Score"":4,""Rationale"":""The answer includes an endoscopy (matches Upper Endoscopy) and mentions blood transfusion with monitoring hemoglobin (matches monitoring and transfusion). It does not include PPI therapy or assessment/treatment of Helicobacter pylori, so those two items receive no points.""}",5.0
,,,,,,,,,,,,,,,,
